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Abstract
Patient-based cancer models are essential tools for studying tumor biology and for the assessment of drug responses in a translational context. We report the establishment a large cohort of unique organoids and patient-derived orthotopic xenografts
(PDOX) of various glioma subtypes, including gliomas with mutations in IDH1, and paired longitudinal PDOX from primary
and recurrent tumors of the same patient. We show that glioma PDOXs enable long-term propagation of patient tumors and
represent clinically relevant patient avatars that retain histopathological, genetic, epigenetic, and transcriptomic features of
parental tumors. We find no evidence of mouse-specific clonal evolution in glioma PDOXs. Our cohort captures individual
molecular genotypes for precision medicine including mutations in IDH1, ATRX, TP53, MDM2/4, amplification of EGFR,
PDGFRA, MET, CDK4/6, MDM2/4, and deletion of CDKN2A/B, PTCH, and PTEN. Matched longitudinal PDOX recapitulate the limited genetic evolution of gliomas observed in patients following treatment. At the histological level, we observe
increased vascularization in the rat host as compared to mice. PDOX-derived standardized glioma organoids are amenable to
high-throughput drug screens that can be validated in mice. We show clinically relevant responses to temozolomide (TMZ)
and to targeted treatments, such as EGFR and CDK4/6 inhibitors in (epi)genetically defined subgroups, according to MGMT
promoter and EGFR/CDK status, respectively. Dianhydrogalactitol (VAL-083), a promising bifunctional alkylating agent in
the current clinical trial, displayed high therapeutic efficacy, and was able to overcome TMZ resistance in glioblastoma. Our
work underscores the clinical relevance of glioma organoids and PDOX models for translational research and personalized
treatment studies and represents a unique publicly available resource for precision oncology.
Keywords Glioma · Glioblastoma · Glioma recurrence · Patient-derived orthotopic xenograft · Organoid · Preclinical
models · Precision medicine · IDH1 · MGMT · VAL-083
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Introduction
Candidate therapeutics for personalized treatment in rare
tumors are difficult to test in clinical trials because of intertumor differences and the limited number of patients representing specific genetic profiles. Adult diffuse gliomas are a
particularly heterogeneous group of rare brain tumors, with
grade IV glioblastoma (GBM) being the most malignant subtype [67]. Despite surgery, radiotherapy and chemotherapy,
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the median survival of GBM patients is 14 months, and the
recurrence is inevitable. GBM, characterized as Isocitrate
dehydrogenase wild type (IDHwt), encompasses tumors
with varying genetic backgrounds that affect distinct signaling networks [11, 14]. They can be classified into molecular
subtypes with differing expression signatures [107, 112],
display variable DNA ploidy [92] and have different DNA
methylation status of the O-6-methylguanine-DNA methyltransferase (MGMT) gene promoter. The latter has been
shown to predict the response to temozolomide (TMZ) [48],
the standard-of-care chemotherapeutic agent approved for
GBM [94]. A separate group of adult diffuse gliomas characterized by activating IDH1 (IDH1mut) or IDH2 (IDH2mut) mutations comprise 1p/19q intact astrocytomas and
1p/19q co-deleted oligodendrogliomas, with varying grades
(II-IV) and survival rates [89], further displaying, e.g., PDGFRA and CDK4 amplification, CDKN2A/B deletion, ATRX,
TP53, or TERT promoter mutations [60, 83, 116], as well as
a glioma CpG Island Methylator Phenotype (G-CIMP) [33,
79]. Several studies point towards an evolution of diffuse
gliomas upon treatment and recurrence, where IDH1/2mut
astrocytomas show most and IDHwt GBMs least changes in
relapsed tumors [5, 29, 38, 57]. Still, most identified changes
appear idiosyncratic and it remains unclear to what extent
the current standard treatment leads to molecular changes
that could affect drug responses for precision medicine. So
far, all targeted treatment attempts in gliomas, e.g., targeting
EGFR [41], have failed in clinical trials and effective treatment strategies are urgently needed.
A major reason for the numerous failures of clinical
trials is the large gap between preclinical models and the
treatment situation in patients where the existing preclinical models inaccurately represent human disease. Robust
brain tumor models, able to reliably predict the sensitivity
of novel personalized treatments in a molecularly defined
group of patients, represent an unmet need [2]. For many
years, the glioma research community relied on a handful of
long-term adherent GBM cell lines that undergo significant
genetic drift. In vivo such cell lines do not recapitulate certain histopathological features of patient tumors and display
inadequate treatment outcomes [32, 34, 103]. Some of these
shortcomings can be avoided by growing cells in defined
serum-free conditions as 3D tumor spheres, adapted from
neural stem/progenitor cultures (generally referred to as glioma stem cell (GSC) or brain-tumor initiating cell (BTIC)
cultures) [18, 62]. However, these are generally limited to
classical GBM [4] and still suffer from a loss of clonal heterogeneity and molecular adaptations to culture conditions [6,
88], in particular loss of focal amplifications related to high
growth factor supply in the medium [66]. Patient-derived
GBM organoids derived in serum-free conditions appear as
a robust in vitro alternative, with a very good preservation
of a heterogeneous tissue structure [49, 51]. However, their
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use is restricted by the limited availability of starting material (large amount of en bloc tissue required [51]), which is
hardly compatible with modern neurosurgical practice of
ultrasonic aspiration, and continuous passaging in vitro may
lead to selection of proliferative GBM tumor cells. For several cancer types patient-derived xenografts (PDXs) established subcutaneously in immunodeficient animals brought
a noteworthy advance, as they allow for propagation of primary patient tumors in less selective conditions and retain
interactions with nonmalignant cells [16]. PDXs were shown
to be more accurate in predicting treatment responses than
common cell lines [46]. Several international initiatives,
such as the EurOPDX and PDXNet consortia, now develop
and standardize PDXs for preclinical studies [42, 72]. However, a recent evaluation of GBM PDXs highlighted drawbacks in retaining chromosomal copy number alterations
(CNAs) [7], and it remains to be seen whether they represent a sustainable model for testing precision medicine regimens. As subcutaneous PDXs do not recapitulate the natural
tumor microenvironment (TME), patient-derived orthotopic
xenografts (PDOX) implanted directly in the brain may be
more adequate for modeling gliomas in their natural milieu,
preserving the physical and physiological constraints of the
blood–brain barrier and the cerebrospinal fluid. To test this,
it is important to assess whether PDOXs can recapitulate
patient-specific genetic and epigenetic features, transcriptomic programs and intratumoral heterogeneity prior and
after treatment, making them amenable as patient avatars
for preclinical precision medicine.
We have previously reported that short-term culture of
mechanically dissociated GBM tissue fragments allows
for derivation of self-organizing 3D organoids, previously
referred to as organotypic spheroids, which preserve tissue
structure, intercellular connections, and TME components
[10, 26]. Intracranial implantation of such GBM organoids
in the brain of immunodeficient rodents allowed for conservation of tumor DNA ploidy and major histopathological features, such as angiogenesis and invasiveness [12,
86, 92, 97, 111]. Such GBM PDOXs recapitulate clinical
responses towards antiangiogenic agents [1, 53]. Here, we
provide systematic evidence that organoid-based glioma
PDOXs are reproducible and clinically relevant models for
functional precision medicine. By combining tumor organoids of various glioma subtypes with in vivo expansion
in the brain microenvironment, we present a cohort of 40
PDOX generated from primary and paired recurrent gliomas
with mixed genetic backgrounds including, among others,
IDH1 mutation and distinct EGFR variants. We show that
these PDOXs preserve key histopathological structures of
malignant gliomas (grade III/IV), recapitulate tumor-intrinsic genetic and molecular features at the individual patient
level and retain intratumoral transcriptomic programs and
stem-cell-associated heterogeneity. This also applies to our
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unique selection of matched PDOX from paired recurrent
glioma samples. We further show that glioma organoids
and PDOXs represent adequate patient avatars for precision
oncology, also in a high-throughput manner. Drug testing in
3D organoids allows for screening in vitro at reasonable cost
with clinically-relevant responses, which can be further validated in vivo. Lastly, we highlight the promising therapeutic
potential of dianhydrogalactitol (VAL-083), a bifunctional
alkylating agent, for treatment of GBM. In summary, our
PDOX live biobank represents an important resource for
accelerating the development of novel treatment strategies
for glioma patients.

Materials and methods
Clinical samples, organoid, and PDOX derivation
Glioma samples were collected at the Centre Hospitalier
of Luxembourg (CHL; Neurosurgical Department) from
patients having given informed consent, and with approval
from the local research ethics committee (National Committee for Ethics in Research (CNER) Luxembourg). For
patient information see Supplementary Table 1, online
resource. Small pieces of tissue were flash frozen for further
molecular analysis. If enough tumor material was obtained,
3D organoids from patient samples were prepared as previously described [12]. Briefly, mechanically minced fresh
human glioma tissue pieces, without enzymatic digestion,
were seeded on agar coated flasks (0.85%) and allowed to
self-organize and form organoids (previously called organotypic spheroids) for up to 2 weeks at 37°C under 5% C
 O2
and atmospheric oxygen in DMEM medium, 10% FBS, 2
mM L-Glutamine, 0.4 mM NEAA, and 100 U/ml Pen–Strep
(all from Lonza). Organoids (generation 0) with a diameter of 300-1000 µm were then implanted in the brain of
immunodeficient mice (NOD/Scid or NSG; 6 organoids
per mice) using a Hamilton syringe (Hamilton, Reno, NV,
USA). Animals (generation 1) were maintained under SPF
conditions and sacrificed at the appearance of neurological
(locomotor problems, uncontrolled movements) or behavioral abnormalities (prostration, hyperactivity) and weight
loss. Optionally tumor volume was monitored by MRI.
Organoids (generation 1) were further prepared from minced
xenografted brains in the same way as for patient tissue and
serially implanted for several generations. No mechanical
and enzymatic digestion was performed prior implantation.
A PDOX model was considered to be established at generation 3, when tumor phenotype and animal survival appeared
stable. For specific purposes, experiments were performed
in nude mice and/or eGFP expressing NOD/Scid mice [78].
Samples P8, P13 and P3 were obtained from Haukeland
University Hospital (Bergen, Norway) following approval
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of the local ethics committee (approval number 2009/117).
For these samples, organoids were initially implanted into
the brain of nude rats (rnu; 10 organoids per rat: P3, P8, P13
models). Kaplan–Meier survival curves were produced in
GraphPad with Wilcoxon signed-rank statistical test. The
handling of animals and the surgical procedures were performed in accordance with the regulations of the European
Directive on animal experimentation (2010/63/EU) and the
Norwegian Animal Act, i.e., the experimental protocols were
approved by the local ethics committee (Animal Welfare
Structure of the Luxembourg Institute of Health; protocols
LRNO-2014-01, LUPA2019/93, and LRNO-2016-01) and
by the Luxembourg Ministries of Agriculture and of Health.
PDOX models are available from the corresponding author
or via EuroPDX consortium (https://www.europdx.eu/) and
PDXFinder (https://www.pdxfinder.org/).

Magnetic resonance imaging
During image acquisition mice were kept under anesthesia with 2.5% of isoflurane, with constant monitoring of
breathing and temperature. For routine follow up, mice were
placed in the MRI (3T MR Solutions) and a Fast Spin Echo
T2-weighted MRI sequence was applied, with field of view
of 25 mm, matrix size of 256 × 256, TE of 68 ms, TR of
3000 ms, and slice thickness of 1 mm. To visualize the contrast enhancement, T1-weighted sequences without and with
contrast injection were used. Fast-Spin Echo T1-weighted
MRI was defined with the following parameters: field of
view of 25 mm, matrix size of 256× 252, TE of 11 ms, TR
of 1000 ms and slide thickness of 1 mm. Contrast agent
(Gadodiamide, Omniscan, GE-Healthcare) at 0.5 mmol/kg
was injected intravenously 1min prior to the scan. MRI data
were analyzed by ImageJ.

Cell lines and cell line‑derived xenografts
Glioma stem-like cell (GSC) cultures (P3NS, P13NS,
T16NS, T158NS, T226NS, T384NS, T394NS, T407NS)
were derived from PDOXs by papain-based enzymatic
digestion of PDOX tissue and cultured as 3D spheres in
serum-free medium based on Neurobasal® base medium
(Life Technologies) supplemented with 1× B27 (Life Technologies) 2 mM l-glutamine, 30 U/ml Pen–Strep, 1 U/ml
Heparin (Sigma), 20 ng/ml bFGF (Miltenyi, 130-093-841)
and 20 ng/ml EGF (Provitro, 1325950500). GSC NCH601,
NCH421k, and NCH644 lines [18] were cultured as nonadherent spheres in DMEM-F12 medium (Lonza) containing 1× BIT100 (Provitro), 2 mM l-Glutamine, 30 U/
ml Pen–Strep, 1 U/ml Heparin (Sigma), 20 ng/ml bFGF
(Miltenyi, 130-093-841), and 20 ng/ml EGF (Provitro,
1325950500). U87 and U251 cells (obtained from ATCC,
HTB-14) were cultured as adherent monolayers in DMEM
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containing 10% FBS, 2 mM l-Glutamine and 100 U/ml
Pen–Strep (all from Lonza). Cell lines were regularly tested
for mycoplasma contamination. Cell lines were authenticated by DNA profiling using an SNP-based multiplex
approach and as compared to the other continuous cell
lines in the DSMZ database. SNP profiles were unique. For
in vivo experiments tumor cells (50,000–100,000 per mouse)
were slowly injected through a Hamilton syringe (Hamilton,
Reno, NV, USA) into the right frontal cortex. The animals
were sacrificed upon weight loss, appearance of severe neurological (locomotor problems, uncontrolled movements) or
behavioral abnormalities (prostration, hyperactivity).

Immunohistochemistry and neuropathological
analysis
Coronal sections from paraffin-embedded brains were
stained with hematoxylin (Dako) and 1% eosin (H&E)
(Sigma). For immunostaining, sections were pretreated
for 5min with Proteinase K (Dako) followed by 30 min
incubation at 95 °C in retrieval solution (Dako). The Dako
Envision+System-HRP was used following the manufacturer’s instructions. Primary and secondary antibodies were
incubated for 1 h. Signal was developed with 3,3′-diaminobenzidine chromogen in 5–20 min. Additional IHC preparations were performed using a Discovery XT automated
staining module (Ventana) and standard protocols (list of
antibodies in Supplementary Table 2, online resource). The
existence of necrosis and the degree of invasion was assessed
on the basis of H&E and human-specific Nestin staining.
Proliferation index was determined as % Ki67-positive cells
per whole cell population. An index of 37% was used to split
Ki67 low and high models. IHC of mouse endothelial cells
(CD31) was performed on isopentane flash-frozen tissues
and cryostat sections (10 µm) were fixed with acetone and
chloroform. Nonspecific binding was blocked with 2% FBS
in TBS and antibodies were incubated for 1 h at RT. Pictures
were acquired with a Leica DMI 6000B microscope. Vessel quantification was done using ImageJ software. Average
vessel area (µm2) was used as a proxy for vessel abnormality.
Vessel area high and low models were analyzed after median
split dichotomization into two groups. Kaplan–Meier survival analyses, including Log-rank and Wilcoxon testing
were performed in GraphPad Prism 8. Other analyses were
performed with two-tailed Student’s t test.

Flow cytometry
Tumor and PDOX tissue was dissociated with MACS Neural
Tissue Dissociation Kit (P) (Miltenyi) following manufacturers’ instructions. For phenotyping flow experiments were
performed as described [47]. Single cell suspensions were
resuspended in DMEM, containing 2% FBS, 10 mM HEPES
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pH 7.4, and DNase I (10 µg/ml; Sigma) at 1 × 106 cells/ml
followed by 90 min incubation with Hoechst 33342 (5 µg/
ml, Bisbenzimide, Ho342; Sigma) at 37 °C. After washing,
cells were resuspended in ice-cold HBSS 2% FBS, 10 mM
HEPES pH 7.4 buffer (100 µl/test). Prior to flow cytometric
analysis, cells were incubated with the IR-LIVE/DEAD®
Fixable Dead Cell Stains (Invitrogen; 1 µg/ml) and appropriate preconjugated antibodies for 30 min at 4 °C in the dark
(Supplementary Table 2, online resource). The data acquisition was performed on a FACS AriaTM SORP cytometer (BD
Biosciences) fitted with a 632 nm (30 mW) red laser, a 355
(60 mW) UV laser, a 405 nm (50 mW) violet laser and a 488
nm (100 mW) blue laser was used. The data analyses were
done with DIVA software (BD Bioscience). For cell sorting,
single cell suspensions were stained with the TO-PRO®-3
shortly before sort. eGFP-negative tumor cells and eGFPpositive mouse non-neoplastic cells were sorted to cold flow
cytometry buffer, centrifuged, and resuspended in organoid
culture medium. Organoids free of non-neoplastic cells were
obtained from sorted eGFP-negative tumor cells by plating 20,000 cells per well of 24-well plates precoated with
agar. For mixed organoids 20,000 sorted tumor cells were
premixed with 2000 sorted eGFP-positive non-neoplastic
mouse cells (10%). Alternative, FACS-sorted GFP-negative
tumor cells were washed in cold HBSS buffer and processed
directly to RNA extraction.

Ploidy assessment
Nuclei were isolated from liquid nitrogen flash frozen PDOX
tumors [92]. Samples were minced in DAPI buffer [10 μg/
ml DAPI in 146 mM NaCl, 10 mM Tris–HCl (pH 7.5), 0.2%
IPEGAL]. Nuclei were disaggregated subsequently with
20G and 25G needles and filtered through a 50 μm and a
30 μm mesh. Tumor nuclei were stained with the humanspecific anti-Lamin A/C-PE antibody (Supplementary
Table 2, online resource). Optionally, PDOX-derived single
cell tumor cells and cell lines were stained with IR-LIVE/
DEAD® Fixable Dead Cell Stains (Invitrogen; 1 µg/ml) and
fixed with cold 80% ethanol. PBMCs were added to each
sample as internal diploid control. Flow analysis was carried out with A
 riaTMSORP or C
 antoTM flow cytometers (BD
Biosystems). DNA content was analyzed with the FlowJo
software.

Extraction and quality control of genomic DNA
DNA from flash frozen primary patient tissue, PDOX tumor
tissue, PDOX-derived organoids, and GSC cultures was
extracted using the AllPrep DNA/RNA Mini Kit® (Qiagen)
following manufacturer’s instructions for “Simultaneous
purification of genomic DNA and total RNA from animal
tissues”. DNA was eluted in 50 μl of Nuclease-free water,
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and concentrations were measured using a NanoDrop 1000
(Thermo Fisher Scientific). Integrity of gDNA was analyzed
with a 1% E-Gel™ EX Agarose Gel (Thermo Fisher Scientific). To obtain DNA from formalin-fixed, paraffin-embedded (FFPE) samples, the tissue block was punched to obtain
a tissue core of 2 mm containing at least 70% tumor tissue.
After a deparaffinization step (Deparaffinization solution,
Qiagen), DNA extraction was performed using QiAamp
DNA FFPE tissue kit (Qiagen) according to the manufacturer’s instruction. DNA concentrations were measured on
the Qubit 4.0 fluorometer (Thermo Fisher Scientific), using
the Qubit dsDNA BR Assay kit (Thermo Fisher Scientific).

Array comparative genomic hybridization
(array‑CGH)
Array-CGHs were performed as previously described
[92] with the following changes. DNA was fragmented
(200–500 bp) using enzymatic digestion with RSA1 and
Alu1 (Agilent Technologies) and labeled with the BioPrime
array-CGH Genomic labeling Kit (Life Technologies) and
Cy3 and Cy5 dyes (GE Healthcare) following standard protocols for Agilent array-CGH (CGH enzymatic protocol
v6.2; Ref # G4410-90010). Female or Male gDNA pool
(Promega) was used as a reference. All labelling reactions
were assessed using a Nanodrop 1000 (Thermo Fisher Scientific) before mixing and hybridized to either a 1 × 1 M,
2 × 400 K, 4 × 180 K or 8 × 60 K SurePrint G3 human
CGH microarray (Agilent Technologies) according to manufacturer’s instructions (CGH enzymatic protocol v6.2; Ref
# G4410-90010). Microarray slides were scanned using an
Agilent 2565C DNA scanner and images were analyzed with
Agilent Feature Extraction version 12.5, using default settings. The data were assessed with a series of quality control
metrics and analyzed using an aberration detection (ADM2)
implemented in the CytoGenomics software versions 4.2 and
5.0.2.5 (Agilent Technologies). Aberrations were called
using the ADM2 algorithm with a threshold setting of 6
and an aberration filter with a minimal number of probes =
3 and a minimal AvgAbsLogRatio = 0.25. For correlation
analysis, each sample was initially processed with Agilent
CytoGenomics 4.2 in order to obtain the characterization of
genomics regions (BED files) described as one of the following events: “amplification”, “gain”, “loss” or “deletion.
Next, from each file, only regions > 50 kb were extracted in
order to construct a reference mapping file using a combination of ‘intersectBed’ and ‘multiIntersectBed’ functions from
the BEDtools suite. Finally, BED files were mapped on that
common reference with their corresponding type of event.
As a consequence the resulting matrix represents features
detectable by any of the four array types. Chromosomes X
and Y were removed. Hierarchical clustering showed no bias
arising from the array type used. Pearson correlation was
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applied to assess relationships between genetic profiles of
each sample. Next, we estimated the effects of the experimental factors on DNA copy number variation data. As these
data were represented by integer values between − 2 and
2, we were unable to fit a global linear model. Instead, we
used a chi-squared contingency table test implemented in
the ‘stat’ package of R. Independently for each factor and
for each DNA site we tested, whether a distribution of copy
numbers is different for different factor levels of the corresponding factor. Mean − log10(p value) and mean chisquared statistics were reported for graphical presentation.

Targeted DNA sequencing
500 ng of extracted gDNA were diluted in 130 μl low TE
buffer (Qiagen) and sheared via sonication on a Bioruptor® UCD-200 (Diagenode) to an average fragment size of
150–300 bp. DNA fragment size was determined using the
DNA 1000 Kit on the Bioanalyzer 2100 (Agilent Technologies). A custom-made Agilent SureSelectXT Target Enrichment Library (Cat No. G9612B) was used for Illumina
Paired-End Multiplexed Sequencing on a MiSeq® instrument (Illumina). The panel design 1 for the Target Enrichment Library was fully adapted from [85] (181 genes and 3
promoters). Further design changes were made using SureDesign—Agilent eArray (Agilent Technologies) to produce
the panel design 2, containing additional regions (234 genes
and 3 promoters). A total of 59 samples were sequenced 22
samples with the panel 1 and 37 samples with the panel 2.
Library preparation was performed according to manufacturers’ instruction. The Illumina MiSeq® Reagent Kit v3
(Cat No. MS-102-3003) was selected applying the Illumina
reagent selection algorithm (https://emea.support.illumina.
com/downloads/sequencing_coverage_calculator.html).
Variant calling was done as follows: Raw sequencing
reads (fastq) were quality trimmed using the tool fastp (v.
0.20.0)[23]. Trimmed reads were aligned to an in silico
fused reference genome (ICRG) containing the human
genome GRCh37.75 (ENSEMBL) and the mouse genome
mm10 using BWA mem (v. 0.7.17) [17]. Reads that mapped
to human chromosomes were extracted from the bam file
using SAMtools (v.1.9) and realigned to the human reference genome only [65]. Duplicates were annotated and
removed using MarkDuplicates under GATK (v.4.0.5.1).
Bam statistics were assessed using SAMtools and compared
between the initial mapping to the ICRG, the realignment
to the human genome and after removing duplicates. Single
nucleotide variants (SNVs) and smaller insertions and/or
deletions (indels) were called in the CLC Genomics Workbench (v.12.0.3) using deduplicated mappings. Variants
were only called in regions with a minimum coverage of
10 reads and a minimal allele frequency of 5%. All variants
that were likely to be polymorphisms and occurred in more
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than 1% of the gnomAD (v.2.0.2) data base were filtered out.
SNVs were annotated with COSMIC (v.89), ClinVar, and
dbSNP (v.150) [61]. The primary focus in SNV calling was
to determine coding changes (missense and inframe mutations), truncating (stop and frameshift mutations) and splice
site mutations. Owing to poor coverage of TERT promoter,
this region was excluded from the global analysis. All filtered variants were manually checked to exclude artefacts
and variants were further classified according to the American College of Medical Genetics and Genomics (ACMG)
[50]. Only pathogenic, likely pathogenic or variants of
uncertain significance (VUS) were reported. For comparing
the %-overlap of variants between patient tissues and PDOX,
the following thresholds were applied: minimum coverage
10, minimum count 2, minimum frequency 5 %. Reads were
mapped with a linear and an affine gap cost mapping and
variants were merged after calling from both mappings.
Structural variants (SVs) and copy number alterations
(CNAs) were analyzed using Manta (v. 1.6.0) and CNVkit
(v.0.9.6) [24, 98]. For these analyzes alignment files with
marked duplicates were used. SVs were annotated with
SnpEff (v. 4.3.1t) [27] and filtered for variants with at least
5 supporting paired and/or split reads. CNAs were called
in two separate groups, as two versions of the sequencing
panels were used and the target region is important for CNA
calling via CNVkit. For panel 1 no reference samples were
sequenced and CNA calling was performed against a flat
reference. CNAs of all samples that were sequenced with
the panel 2 were normalized against a reference created
from normal samples including the commercial available
male (Cat No. G1471) or female (Cat No. G1521) references from Promega (Madison, Wisconsin, US) and DNA
from blood of two patients. Segmentation was performed
using circular binary segmentation according to default settings. Gene metrics were determined for all variants with a
minimum log2 deviation of 0.4. Workflow automation was
performed using the workflow manager snakemake (v.5.6.0)
under conda (v.4.7.12) [58]. Additional data handling was
performed applying R (v.3.6) in the environment of RStudio
(v.1.1.456). All CNAs and the SVs in EGFR were visualized, manually checked, and compared to available data from
array-CGH and array-based DNA methylation analysis.
Subclonal deconvolution via PyClone was performed
in parallel with the above data in an independent manner. PyClone input requires variants and copy number. To
acquire these data, reads were aligned to hg38, processed
with Picard’s MarkDuplicates {http://broadinstitute.githu
b.io/picard/}, and GATK indel realignment and base recalibration performed [105]. Variants were called using mpileup
(Samtools v.1.9) [65] and Varscan 2’s (v.2.4.4) pileup2snp
and mpileup2indel commands [65] with default settings but
a p value of 1.00. Only positions in targeted regions were
kept. Variants in dbSNP were filtered out. Absolute copy
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numbers were estimated using array-CGH. Log2 ratios were
segmented using DNAcopy (v1.52.0) [87]. A custom script
estimated purities and absolute copy numbers based on the
assumption that chr7 likely had a clonal single copy gain,
resulting in inference of one copy loss of chr10 and one
copy gains of chr19 and chr20 (common events in GBM)
in all analysed samples (T192, T233, T251, T158, T347,
and T470), validating this approach. PyClone (v.0.13.1) [84]
was run under default settings, with the addition of ‘–prior
total_copy_number’ to indicate the use of total copy numbers. Purities were taken from the array-CGH estimates for
biopsies, and was set to 1.00 for PDOX samples.

Digital PCR
Digital PCR was used to detect and quantify IDH1 R132H
in genomic DNA using QuantStudio 3D Digital PCR System and IDH1 Digital PCR Mutation Detection Assays from
Thermo Fisher (Assay ID # Hs000000036_rm for c.395G>A
(p. R132H)) according to the manufacturer’s instructions.
The reaction volume was 14.5 µl containing 7.5 µl QuantStudio 3D Digital PCR Master Mix v2 (Thermo Fisher Scientific, cat#: A26359), 0.73 µl of assay and sample DNA. Each
assay contained forward and reverse primers, and 2 specific
dye-labeled probes. The first one with a Vic reporter dye
linked to the 5′end and an MGB linked to the 3′end to detect
the WT allele. The second one with a FAM reporter dye
at the 5′end and an MGB at the 3′end to detect the mutant
allele. The thermal cycling conditions were 96 °C for 10
min; 39 cycles of 60 °C for 2 min and 98 °C for 30 s; final
extension at 60 °C for 2 min. Two replicates of each sample were run and DNA input amount was 20 ng per chip.
Human Genomic DNA Male (Promega, cat # G1471) and
IDH1 R132H Reference Standard (Horizon, cat # HD677)
were used as wild type reference DNA and positive reference
respectively. Data analysis was done with the QuantStudio
3D Analysis Suite Cloud Software version 3.1.5; chips with
< 15,000 partitions above the default quality threshold were
omitted.

Array‑based DNA methylation Analysis
Methylation arrays with Infinium® MethylationEPIC were
processed by the Helmholtz Zentrum Muenchen (Research
Unit of Molecular Epidemiology/Institute of Epidemiology,
German Research Center for Environmental Health, Neuherberg, Germany) [59] or by the Laboratoire National de
Santé in Luxembourg. Bisulfite conversion of 250–500 ng of
gDNA was done using the EZ DNA Methylation Kit (Zymo
Research) according to manufacturer’s procedure, with
the alternative incubation conditions recommended when
using the Illumina Infinium® Methylation Assay. After
bisulfite treatment, Infinium HD FFPE Restore kit (Illumina)
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protocol was performed on 8 µl of DNA from FFPE samples. Genome-wide DNA methylation was assessed using
the HumanMethylationEPIC BeadChip (Cat No. WG-3171001), following the Illumina Infinium® HD Methylation
protocol. This consisted of a whole genome amplification
step using 4 µl and 8 µl (for fresh-frozen and FFPE samples,
respectively) of each bisulfite converted sample, followed by
enzymatic fragmentation, and hybridization of the samples
to BeadChips (Illumina). After a step of single-nucleotide
extension, the BeadChips were fluorescently stained and
scanned with Illumina HiScan SQ scanner or iScan System. Additional Illumina HumanMethylation450 BeadChips
were processed according to manufacturer’s instruction at
the German Cancer Research Center (DFKZ) Genomics and
Proteomics Core Facility. Raw Intensity Data files (.idat)
were exported from the BeadArray. Pearson correlation was
applied to assess relationships between epigenetic profiles of
each sample. The R package ‘RnBeads’ was used to generate individual 450 k and EPIC RnBeadSets [74] that were
normalized using the ‘BMIQ’ method [100]. Both platforms
were combined using the ‘rnb.combine.arrays’ function in
order to extract only common sites present in both objects
with corresponding DNA methylation level. The DNA methylation level for each locus was measured as a beta-value
score; that can range from zero to one with scores of zero
indicating completely unmethylated DNA and scores of one
indicating complete methylated DNA. Hierarchical clustering showed no bias arising from the array type used. Pearson
correlation and Principal component analysis (PCA) were
applied to assess relationships between epigenetic profiles
of each sample.
As several of the considered factors were strongly correlated, we estimated their importance by consequent fitting
unavailable ANOVA models, independently for each CpG
site and factor. Mean F statistics over all variable CpG cites
was then used to illustrate the importance of the factors. To
detect differentially methylated regions (DMRs) or CpGs
(DMCs), IDAT files were subjected to background correction, global dye-bias normalization, calculation of DNA
methylation level, and detection p values using ‘methylumi.
noob’ within the ‘RnBeads’ package. Differential methylation analysis was conducted on genomic site and region level
according to sample groups (Patient vs. PDOX or IDHwt
vs. IDH1mut) using ‘limma’ and fitted using an empirical
Bayes approach on M values [90]. In general, array probes
were divided into 4 different genomic regions, giving info
on functional genomic distribution: (1) tiling regions with a
window size of 5kb distributed over the whole genome, (2)
genes and (3) promoters annotated with Ensembl gene definitions from the biomaRt package. Promoters were defined
as the region spanning 1500 bases upstream and 500 bases
downstream of the TSS of the corresponding gene. (4) CpG
islands tracked from UCSC genome browser. Furthermore,
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probes were divided into those within CpG islands (CGI),
in CGI shores, shelves, or open seas (with or without overlapping gene bodies). In the comparison between ‘Patient’
and ‘PDOX’, the following criteria were selected: adj. p
value < 0.01, absolute difference in mean methylation β
value > 0.2. Beta value distribution plots for probe categories (‘Open Sea’, ‘Shelf’, ‘Shore’ or ‘Island’) were extracted
from the integrated ‘Exploratory Module’ from ‘RnBeads’.
Global beta value density plots for longitudinal samples
were generated using the ‘minfi’ package in R, after Noob
background correction and global dye-bias normalization.
The analysis of CpG methylation signatures was performed
as described previously [33], where DNA methylation profiles were compared to a large cohort of the patient glioma
tumors. DNA methylation-based glioma classification was
performed by referencing data to the dataset of over 2800
neuropathological tumors at https://www.molecularneurop
athology.org/mnp as described previously [20] .

Genome‑wide gene expression analysis
Total RNA was extracted using the QIAGEN® RNeasy
Mini Kit according to the manufacturer’s protocol. GeneChip® Human Gene 1.0ST Arrays were used to determine the expression profiles. Total RNAs were processed
using the Ambion WT expression kit (Life Techniologies)
and the Affymetrix WT Terminal & Labeling kit before
being hybridized on Affymetrix arrays according to the
manufacturer’s instructions (protocol P/N 702808 Rev.6).
Upon hybridization, microarrays were washed, stained,
and scanned according to manufacturer’s standard procedures. Affymetrix CEL files containing hybridization raw
signal intensities were processed to gene expression signals
using the RMA (robust multichip average) algorithm implemented in the oligo package (version 1.44.0). hugene10sttranscriptcluster.db package version 8.7.0 was then used to
map Affymetrix ID to entrez gene ID. R statistical environment was used for hierarchical clustering, principal component analysis and for empirical Bayesian statistics (LIMMA
[90], R/Bioconductor). List of differentially expressed genes
(DEG) were obtained with the eBayes/LIMMA. FDR was
calculated with the Benjamini and Hochberg approach [8].
Thresholds were set up for FDR < 0.01 and absolute fold
change (abs(FC)) ≥ 2. The Metascape® database [118] was
used for data mining.
The similarity between our patient biopsies, PDOXs and
cell lines with GBM tumors from The Cancer Genome Atlas
(TCGA) cohort (538 GBM samples) was investigated using
gene expression data [19]. Our cohort’s data were ranked
based on their interquartile ranges to select the top-5000
(most variable) probes across samples. We focused on
probes with mapped gene symbols, for genes with multiple
probes their expression values were (mean) merged with
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Babelomics 5 [3]. Filtering resulted in 4069 unique gene
symbols. TCGA data were downloaded from The Broad
Institute GDAC Firehose (http://gdac.broadinstitute.org),
and the preprocessed gene expression data (RSEM values)
were analyzed. Gene symbols from our cohort were matched
to the TCGA data, and 2420 unique symbols were unambiguously found in both datasets. Using the expression data
for these genes, we measured (Spearman) correlation coefficients between our cohort samples and TCGA tumors. The
resulting correlations with the TCGA tumors were ranked
and graphically visualized in terms of individual samples
and sample groups. Analyses were implemented with the R
statistical language, packages corrplot, and ggplot2 (https://
www.r-project.org).
Consensus independent component analysis (ICA), a
data-driven dimensionality reduction method that performs
a matrix decomposition, was applied to assess signals arising
from nonmalignant cells. ICA with k components represents
log2-transformed gene expression matrix X as a matrix product of matrices S (signals) and M (weights). The first shows
contribution of genes in k statistically independent signals.
Biological meaning of these signals was detected by functional annotation of the most contributing genes. In order to
improve reproducibility of ICA decomposition, which can
be affected by the selection of initial estimations, we applied
consensus ICA approach [76]. ICA was run multiple times
and the resulted matrices S and M were mapped and averaged between the runs. The analysis of the cell lines and
TCGA reference dataset was performed as described in [76].

Single cell RNA‑Seq using Drop‑Seq
For scRNA-seq experiments PDOXs derived in nude mice
were used. To obtain a pure population of single viable cells
and to distinguish human tumor cells from mouse TME subpopulations PDOXs were dissociated and FACS-sorted (P3,
P8, P13) or MACS-purified (T16, P13). For FACS we have
separated hCD90 positive tumor cells from hCD90 negative
mouse TME subpopulations [36]. MACS-based purification
was performed with Myelin Removal Beads II followed by
Mouse Cell Depletion kit (Miltenyi Biotec) according to
manufacturer’s protocols. Prior to cell loading on the Dropseq chips, the viability of cells was verified and concentration was adjusted to ~ 150 cells/μl as optimal concentration
to achieve single cell encapsulation within each droplet of
~ 1 nl. All samples analyzed had a cell viability > 95%.
Microfluidics devices were fabricated using a previously
published design [70]. Soft lithography was performed using
SU-8 2050 photoresist (MicroChem) on 4” silicon substrate
to obtain a feature aspect depth of 100 μm. After overnight
silanization (using Chlorotrimethylsilane, Sigma), the wafer
masks were used for microfluidics fabrication. Drop-seq
chips were fabricated using silicon based polymerization
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chemistry. Briefly, Polydimethylsiloxane (PDMS) base
and crosslinker (Dow Corning), were mixed at a 10:1 ratio,
mixed and degassed before pouring onto the Drop-seq master template. PDMS was cured on the master template, at
80 °C for 2 h. After incubation and cooling, PDMS slabs
were cut and the inlet/outlet ports were punched with 1.25
mm biopsy punchers (World Precision Instruments). The
PDMS monolith was plasma-bonded to a clean microscopic glass slide using a Harrick plasma cleaner. Immediately after pairing the plasma-treated surfaces of the PDMS
monolith and the glass slide, flow channels of the Drop-seq
chip were subjected to a hydrophobicity treatment using
1H,1H,2H,2H-Perfluorodecyltrichlorosilane (in 2% v/v in
FC-40 oil; Alfa Aeser/Sigma). After 5 min of treatment,
excessive silane was blown through the inlet/outlet ports.
Chips were further incubated at 80 °C for 15 min.
Experiments followed the original Drop-seq protocol
[70] with minor changes. Synthesized barcoded beads
(Chemgenes corp., USA) were co-encapsulated with cells
inside the droplets containing lysis reagents using an optimal bead concentration of 200 beads μl−1 in Drop-seq Lysis
buffer medium. Cellular mRNA was captured on the beads
via barcoded oligo (dT) handles synthesized on the surface.
For cell encapsulation, 2 ml of cell and bead suspensions
were loaded into 3 ml syringes (BD), respectively. To keep
beads in homogenous suspension a microstirrer was used
(VP scientific). The QX 200 carrier oil (Bio-rad) used as
continuous phase in the droplet generation was loaded into
a 20 ml syringe (BD). For droplet generation, 3.6 ml per h
and 13 ml per h were used in KD scientific Legato syringe
pumps for the dispersed and continuous phase flows, respectively. After stabilization of droplet formation, the droplet
suspension was collected into a 50 ml Falcon tube. Collection of the emulsion was carried out until 1 µl of the
single cell suspension was dispensed. Droplet consistency
and stability were evaluated by bright-field microscopy
using INCYTO C-Chip Disposable Hemacytometer (Fisher
Scientific). Bead occupancy within droplets was carefully
monitored to avoid multiple bead occupancy. The subsequent steps of droplet breakage, bead harvesting, reverse
transcription, and exonuclease treatment were carried out
in accordance to [70]. RT buffer contained 1× Maxima RT
buffer, 4 % Ficoll PM-400 (Sigma), 1 μM dNTPs (ThermoScientific), 1 U/ml Rnase Inhibitor (Lucigen), 2.5 μM
Template Switch Oligo, and 10 U/ml Maxima H-RT (ThermoScientific). Post Exo-I treatment, the bead counts were
estimated using INCYTO C-Chip Disposable Hemacytometer, and 10,000 beads were aliquoted in 0.2 ml Eppendorf
PCR tubes. PCR mix was dispensed in a volume of 50 μl
using 1× Hifi HotStart Readymix (Kapa Biosystems) and
0.8 mM Template-Switch-PCR primer. The thermocycling
program for the PCR amplification was modified for the final
PCR cycles by 95 °C (3 min), four cycles of 98 °C (20 s),
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65 °C (45 s), 72 °C (3 min), 10 cycles of 98 °C (20 s), 67 °C
(20 s), 72 °C (3 min) and followed by a final extension step
of 72 °C for 5 min. Post PCR amplification, libraries were
purified with 0.6× Agencourt AMPure XP beads (Beckman
Coulter), in accordance with the manufacturer’s protocol.
Finally, the purified libraries were eluted in 20 μl RNAse/
DNAse-free molecular grade water. Quality and concentration of the sequencing libraries were assessed using BioAnalyzer High Sensitivity Chip (Agilent Technologies).
The 3′end enriched cDNA libraries were prepared by
tagmentation reaction of 600 pg cDNA library using the
standard Nextera XT tagmentation kit (Illumina). Reactions
were performed according to the manufacturer’s instructions, samples were barcoded using the N7xx index series
and 400 nM custom P5 hybrid primer: (AATGATACGGCG
ACCA
 CCG
 AGA
 TCT
 ACA
 CGC
 CTG
 TCC
 GCG
 GAA
 GCA
 GT
GGTATCAACGCAGAG T*A*C). The PCR amplification
cycling program used was: 95 °C 30 s; fourteen cycles of:
95 °C (10 s), 55 °C (30 s), 72 °C (30 s) followed by a final
extension step of 72 °C (5 min). Libraries were purified
twice to reduce primers and short-DNA fragments with 0.6×
and 1× Agencourt AMPure XP beads (Beckman Coulter),
respectively, in accordance with the manufacturer’s protocol. Finally, purified libraries were eluted in 15 μl molecular
grade water. Quality and quantity of the tagmented cDNA
library was evaluated using BioAnalyzer High Sensitivity
DNA Chip. The average size of the tagmented libraries prior
to sequencing was between 400 and 700 bps. Purified Dropseq cDNA libraries were sequenced using Illumina NextSeq
500 with the recommended sequencing protocol except for
6pM of custom primer (GCCT
 GTC
 CGC
 GGA
 AGC
 AGT
 GG
TATCAACGCAGAGTAC) applied for priming of read 1.
Paired end sequencing was performed with the read 1 of
20 bases (covering the random cell barcode 1–12 bases and
the rest 13–20 bases of random unique molecular identifier
(UMI) and for read 2 the 50 bases of the genes.
Bioinformatic processing followed the DropSeq protocol [70] using the DropSeq tool version 1.16. In brief,
FASTQ files were assembled from the raw BCL files
using Illumina’s bcl2fastq converter and ran through the
FASTQC codes [Babraham bioinformatics; https://www.
bioinformatics.babraham.ac.uk/projects/fastqc/] to check
library qualities by the assessment parameters (a) quality
per base sequence, (b) per base N content, (c) per base
sequence content and d) over-represented sequences.
Libraries with significant deviation were re-sequenced.
FASTQ files were subsequently merged and converted
to binaries using PICARD’s fastqtosam algorithm. The
resulting digital gene expression matrix (DGE) was first
cut based on knee plot analysis and subsequently filtered
by the Seurat version 3 and Monocle version 2 packages
(http://cole-trapne ll-lab.github .io/monocl e-releas e/) in
R (version 3.6.0) based on ribosomal and mitochondrial
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genes as well as on low transcript content. The following
threshold filters were used: only cells that expressed at
least 200 genes and presented 1 x106 total mRNAs, and
only genes which were expressed in at least 5 cells were
considered for further analysis. To normalize for transcript
capturing between the beads, the averaged normalized
expression levels (log2(TPM+1)) were calculated. After
filtering and normalization, our dataset included 3138 cells
(per sample cell counts: P3 = 543 cells, P8 = 502 cells,
P13 = 1295, T16 = 798 cells). To examine relative expression levels, we centered the data by subtracting the average expression of each gene from all cells. Digital gene
expression matrix of the TME subpopulations of PDOX
P8 and normal mouse brain was filtered and normalized
as described above. After filtering and normalization, the
dataset included 892 cells (per sample cell counts: P8 =
453 cells, Control = 439 cells). Dimensionality reduction
and gene expression markers identification and visualization were done using UMAP implemented in the Seurat
package version 3 [15, 93].
The cell cycle and hypoxia meta-signatures were determined based on the respective Molecular Signatures Database (MsigDB [95]) and only correlated genes (R > 0.3)
were considered. The relative expression of common
signature genes between all samples was depicted in the
expression heatmaps. For each cell cycle and hypoxia signature, a specific meta-module was defined, taking into
account all genes that were common among the samples,
and the average relative expression for each specific metamodule was calculated. These meta-modules were used
to score the cells by the average relative expression of all
genes in the meta-module, and cells were sorted according
to these scores. The global score for each sample was calculated as the average of all cell cycle and hypoxia metamodules expression. Meta-modules were also defined for
the G1/S and G2/M phases of the cell cycle, which enabled cells to be classified as cycling (mean relative expression ≥ 0.1 and qval < 0.05) and noncycling (mean relative expression < 0.1 and qval > 0.05). For each cell, the
mean relative expression of unique tumor subtype genes
was calculated and used to create a score for each respective subtype. The minimum and maximum score values
were determined and only cell scores above the threshold
(qval > 0.001) were used to generate the tumor subtype
heatmaps. Single cell signature scores for cellular phenotypic states and meta-modules (MES, AC, NPC, and
OPC-like) were implemented as described by Neftel et al.
[77]. TCGA subtypes of single cells were assessed based
on signatures described in Wang et al. [112]. Owing to
the limitations of Drop-seq data, the signature scores for
TCGA subtypes were determined according to scripts from
Neftel et al. [77].
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Western blot
Protein extraction was performed using minimal amounts
of RIPA buffer (Thermo Fisher Scientific, Cat No. 89901)
containing 1x protease inhibitor (Merck, cOmplete® protease
inhibitor cocktail) and on ice incubation for 15min followed
by brief sonication and a centrifugation step (13.000 ×g,
5 min, 4 °C) to remove cellular debris. iProtein extracts were
resolved in NuPageTM 4–12% BisTris Protein Gels (Cat No.
NP0321BOX, Thermo Fisher Scientific, MA, US), and blotted onto an I nvitrolonTM PVDF (Thermo Fisher Scientific,
Cat No. LC2005) or a Nitrocellulose membrane (Lifetech,
Cat No. IB23001) according to standard protocols. After
incubation with 5% nonfat milk in TBST (10 mM Tris, pH
8.0, 150 mM NaCl, 0.5% Tween 20) for 60 min, the membrane was rinsed with TBST and incubated with primary
antibodies (Supplementary Table 2, online resource). Membranes were washed three times for 10 min and incubated
with horseradish peroxidase (HRP)-coupled secondary antibodies (Jackson ImmunoResearch) for 1h at RT. Blots were
washed with TBST three times, once with TBS, developed
with a chemiluminescent substrate (ThermoFisher) and
imaged with the ImageQuant 350 scanning system (cooledCCD camera, GE Healthcare).

Ex vivo compound screening in 384‑well plate
format
PDOX tumors were dissociated with the MACS Neural
Dissociation kit (Miltenyi Biotec) according to manufacturer’s instructions. Mouse cells were removed with Mouse
Cell Depletion kit (Miltenyi Biotec). Tumor cells were
seeded 1000 cells/well in organoid medium in 384-well
plates (PrimeSurface®, S-Bio) and cultured for 72 h to
allow organoid formation. Organoids were treated with the
following compounds: Erlotinib (EGFR, SelleckChem),
Gefitinib (EGFR, SelleckChem), AZD3759 (EGFR,
SelleckChem), AG-490 (JAK2, EGFR, SelleckChem),
Daphnetin (EGFR, PKA/C, SelleckChem), Palbociclib
(CDK4/6, SelleckChem), Abemaciclib (CDK4/6, SelleckChem), TMZ (Sigma) and 1,2:5,6-Dianhydrogalactitol
(VAL-083, Delmar) in a fourfold and seven-point serial
dilution series ranging from 1 µM to 1 mM (VAL-083,
TMZ) or 12 nM to 48 μM (remaining inhibitors). After
3 (TMZ, VAL-083) or 6 (remaining inhibitors) days of
incubation at 37 °C in a 5% CO2 humidified incubator for
respective inhibitors, cell viability and cytotoxicity were
measured with CellTiter-Glo ®2.0 and CellToxTM-Green
assays (Promega) respectively according to the manufacturer’s instructions with a ClarioStar plate reader (BMG
Labtech). The relative cell viability for each dose was
obtained by normalization with untreated control (VAL083) or dimethyl sulfoxide (DMSO, Sigma, remaining
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compounds) per each plate or condition. Dose response
curves (DRCs) were fitted using GraphPad Prism 8: bestfit lines and the resulting I C50 values were calculated using
log[inhibitor] versus normalized response—variable slope
(four parameters). The area under the curve (AUC) for
each DRC was calculated using GraphPad Prism 8. The
experiments were performed with one (VAL-083, TMZ)
or two (EGFR and CDK4/6 inhibitors) biological replicates, each comprising three technical replicates per
PDOX model per each drug concentration. Statistical differences between genetically defined PDOXs groups were
performed with unpaired 2-tailed t test. For LIVE/DEAD
double labeling, organoids were incubated with 2 mM
Calcein-AM and 4 mM Ethidium homodimer-1 (LIVE/
DEAD assay kit, Molecular Probes) for up to 6 h. Imaging of viable (green) and dead (red) cells was done using
LSM510 or LSM880 Confocal Laser microscopes (Zeiss).

Cell printing and high‑throughput drug screening
procedure
PDOX T434 tumors were dissociated with the MACS Neural Dissociation kit (Miltenyi Biotec) according to manufacturer’s instructions. Mouse cells were removed with
Mouse Cell Depletion kit (Miltenyi Biotec). Tumor cells
were mixed with 1% alginate (ratio of 1:1) and printed on
384-pillar array (1000 cells with 250 nl) by ASFA Spotter
ST (Medical & Bio Device, Suwon-si, South Korea). The
pillars were washed by carefully combining the cell-pillar
plates with 384-well plates containing 40 µl of cell culture
medium (DMEM (Biowest), 10% FBS, 1% Pen–Strep, 4x
NEAA (Lonza), 1% Ultraglutamine (Lonza)) in each well,
and incubation for 30 min at 37 °C. The pillar plates were
then combined with 384-well assay plates containing cell
culture medium and incubated for 3 days at 37 °C and 5%
CO2 atmosphere. The pillar plates were then transferred
to compound plates where the cells immobilized in alginate were exposed for 7 days to 41 FDA-approved drugs,
in a fourfold and seven-point serial dilution series from
7.3 nM to 30 μM in duplicates. Bortezomib was used as
an internal control. To determine end-point cell viability,
the cells were stained using Calcein AM live cell staining
and the images were acquired using High Content imaging
instrument (CV8000, (Yokogawa, Tokyo, Japan). Cell viability was calculated based on Calcein AM fluorescence.
The relative cell viability for each dose was obtained by
normalization with dimethyl sulfoxide (DMSO) per each
plate. The experiment was performed in two replicates on
different 384 well plates. Dose Response Curves (DRC)
were fitted using GraphPad Prism 8 (GraphPad). The AUC
for each DRC was calculated using GraphPad Prism 8.
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In vivo tumor treatment
T16 GBM organoids were orthotopically implanted into the
right frontal lobe of Swiss nude mice. Animals were monitored daily and the following criteria were evaluated: (1)
loss of > 10% of body weight, (2) exhibition of strong neurological signs (3) increased kyphosis or (4) swollen belly.
Tumor growth was monitored by MRI (T1- and T2-weighted
MRI protocol; 3T MRI system, MR Solutions). 35 days postimplantation most mice had visible tumors and were randomized into 4 treatment groups (7 mice per treatment group,
6 mice per control group): Control, Bevacizumab (Avastin)
treatment, VAL-083 treatment and combined Bevacizumab
+ VAL-083 treatment. Drug concentrations and treatment
schedule were as follows: Bevacizumab – 20 mg/kg, 1×
week, VAL-083 − 3.5 mg/kg, 3× week. Control animals
received saline (NaCl 0.9%) 4× week. Compounds and
saline were delivered by intraperitoneal injections. Bevacizumab and VAL-083 injections were performed on different days. 49 days after implantation MRI T2 was applied
to monitor tumor progression. T1 with contrast agent was
applied to several mice to evaluate the response of tumor to
Bevacizumab. 56 days after implantation one mouse in control group showed neurological symptoms and was euthanized directly after MRI. T2 and T1 + contrast MRI was
applied to all mice. Remaining mice were euthanized the
following day before mice developed symptoms and brains
extracted. Tumor volume (mm3) was measured in ImageJ as
the sum of area obtained by tumor delineation in each slice
and multiplying by slice thickness (1mm). Growth rate (GR)
was calculated using the TV measurement as GR = 100 ×
log (TVf/TV0)/(tf−t0), where TVf and TV0 are the tumor
volumes at the late (day 56) and early (day 35 or day 49)
time points, respectively, and tf−t0 is the difference in days
between the time points. Tumor volumes are expressed in
mm3 and GR in % per day [80]. Statistical difference was
assessed with ANOVA with Turkey’s multiple comparison
test.

Statistical tests
Different statistical approaches have been applied based
on the data type and measurements across the manuscript.
Statistical tests are described in each paragraph above corresponding to the associated experimental procedures. If not
specified above, significant differences were calculated with
the Student’s t test.

Data availability
Our PDOX models are freely available to the scientific
community. To facilitate the access to established models,
we provide detailed information for the best characterized
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models via PDXFinder (https://www.pdxfinder.org/) [30].
New models will be regularly added to the resource with
molecular and histopathological characterization. Our collection is also part of the EuroPDX consortium (https://
www.europdx.eu/). Models are available from the corresponding author on reasonable request. The sharing procedure will depend on the expertise of the requesting laboratory. Groups experienced in organoid culture and intracranial
implantation will be provided with the organoids. For less
experienced groups we provide additional training or perform collaborative experiments in house. For small scale
experiments we provide ready-to-use material, e.g., tissue
sections, cryopreserved organoids, or single cells.’
Molecular data are available in the Gene Expression
Omnibus repository (https://www.ncbi.nlm.nih.gov/geo/)
under accession numbers as follows: (1) array-CGH:
GSE137959; (2) DNA methylation: GSE137845; (30 gene
expression: GSE134470; (4) scRNA-seq:GSE128195. Targeted DNA sequencing is available in the Sequence Read
Archive (https: //www.ncbi.nlm.nih.gov/sra) under accession
number PRJNA627814.

Results
Glioma organoids and PDOXs can be generated
across diverse clinical high‑grade glioma specimens
Fresh tumor samples of 241 glioma patients (189 GBM, 52
grades II-III gliomas) were collected at surgery, including
from multifocal samples and longitudinal samples of patients
undergoing sequential operations (Fig. 1a, b, Supplementary Table 1, online resource). Organoids of 300–1000 µm
were obtained by mechanical dissociation of tissue, without enzymatic digestion, followed by self-aggregation in
short-term culture (up to 14 days). These cultures represent
self-organizing structures, which preserve a heterogeneous
3D tumor tissue organization, including cell–cell interactions, non-neoplastic cells of the tumor microenvironment
(TME) and extracellular matrix components. The initial
culture step allows to shed necrotic cells and to standardize the organoids for intracranial implantations. Sufficient
material was available for cultures from 72% (136 GBM,
37 grades II–III gliomas, total 173) of collected patient
samples, of which 79% GBMs (107/136) and 68% (25/37)
of grades II–III gliomas presented high quality organoids.
Common reasons for lack of healthy organoids were
necrotic tissue, tissue damage during surgical procedure or
insufficient material. In general, organoids self-assembled
into 3D structures within 3–5 days. The proliferation and
growth of organoids was generally limited, but variable
and patient specific. We used patient-derived organoids for
downstream applications within 10–14 days of short-term
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culture. Occasionally we mechanically recut larger organoids
to ensure good quality and avoid necrosis. Although organoids can remain viable in culture over longer periods, they
often fuse to re-aggregate into larger structures. We have not
attempted further expansion and passaging in order to limit
in vitro selection processes. Organoids were either frozen
in DMSO-containing medium for later recovery or directly
implanted into the rodent brain. No enzymatic or mechanical
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dissociation of organoids was applied prior implantation or
cryopreservation.
To date, out of the 173 generated glioma organoids, we
have performed 49 implantations into the mouse brain (41
GBM and 8 grade III gliomas). Organoids were implanted
in immunodeficient mice (NOD/Scid, NSG) and tumors
developed within 4–57 weeks depending on the parental
tumor (Generation 1). The developed tumors were further

Acta Neuropathologica (2020) 140:919–949
◂Fig. 1  Clinical and histological characterization of the glioma PDOX

cohort. a Schematic of derivation of PDOXs from primary and recurrent patient gliomas. Treatment refers to patients. PDOXs enable
tumor expansion via serial transplantation, organoid-based in vitro
assays including drug screening, genetic manipulations, and derivation of long-term in vitro sphere cultures. b Clinical patient information of corresponding 40 PDOXs (from 32 patients). PDOXs derived
from longitudinal or multifocal samples of the same patients are
highlighted. See Supplementary Table 1, online resource for more
information. c MRI, Hematoxylin/Eosin, human-specific Nestin,
and mouse-specific CD31 stainings were performed to assess histopathological characteristics of PDOXs. Representative PDOX models displaying a range of invasive and angiogenic features are shown.
Scale bars represent 1mm (black) and 100µm (white). d Kaplan–
Meier survival curves of PDOXs divided in high and low Ki67 positive cells (mean Ki67 positive cells per model - split by median),
***pvalue < 0.001 (Wilcoxon signed-rank test). Mean survival of each
model ≥ generation 3 was plotted in each group. e Kaplan–Meier survival curves of PDOXs divided by vessel area (Average vessel area in
µm—split by median value), ns = not significant (Wilcoxon signedrank test). Mean survival of each model ≥ generation 3 was plotted
in each group. f Histopathological comparison of the same PDOXs
derived in mice or rats. Angiogenic features are amplified in the rat
brain (arrows, abnormal vessel morphology; stars, pseudopalisading
necrosis; black bar, 1 mm; white bar, 100 µm). Examples are shown
for pronounced invasive histopathology (P8), intermediate (T16) and
increased angiogenic (P13) growth. Scale bars represent 1 mm. See
more examples in Supplementary Fig. 1d, online resource

resected from the mouse brain and organoids (Generation
1) were obtained by applying the same protocol as for
patient tumor tissue. IDHwt GBM organoids survived well
a freezing–defrosting procedure, while IDH1mut (R132H)
gliomas were more fragile, often requiring implantation
of freshly prepared organoids or small unprocessed tissue fragments. Generally, mice showed a longer latency
period at first passage (Supplementary Fig. 1a, online
resource) and the most PDOXs reached a stable tumor
development time per patient tumor at Generation 2–4.
Successful engraftment and PDOX propagation via serial
transplantation (> 3 passages) were obtained for 86%
of GBMs (35/41, 6 failed due to poor organoid quality),
25% of grade III gliomas (2/8, no association with organoid quality). Grade II gliomas were not systematically
implanted because of minimal prior success. Rare activating IDH2mut (R172K) gliomas are not yet present in
the cohort. Three additional GBMs (PDOXs P3, P8, and
P13) were initially derived in nude rats [111] and were
further serially transplanted in mice. To date, we have
generated a cohort of 40 glioma PDOX models from 32
patients, displaying different clinical characteristics and
molecular backgrounds (Fig. 1b, Supplementary Table 1,
online resource). Our PDOX cohort contains tumors from
primary untreated gliomas as well as recurrent tumors
after treatment. We obtained paired longitudinal samples,
before and after treatment, from 7 patients and were able to
generate 15 corresponding PDOXs. One patient (LIH0831)
with a multifocal GBM led to 2 PDOX models derived
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from tumor tissue collected from two distinct locations.
Out of 25 PDOX models cultured in serum free medium
in vitro, 8 glioma stem cell-like (GSC) lines could be
propagated long term, including 2 cell lines carrying the
IDH mutation (Supplementary Table 1, online resource).

Glioma PDOXs display a range of invasive
and angiogenic glioma features
PDOXs derived in immunodeficient mice preserved the
major histopathological features of patient tumors and displayed a gradient of invasiveness and vascular pathology
depending on the tumor of origin (Fig. 1c). Angiogenic
tumors tended to grow in a more circumscribed manner
and showed contrast enhancement on MRI, indicative of
blood brain barrier disruption. In line with our previous
report [12], mouse survival was a result of a combination of
histopathological features (vascular proliferation, necrosis,
and invasion) and proliferation index, where high proliferation correlated significantly with poor prognosis (Fig. 1d, e,
Supplementary Table 1, online resource). Models derived
from relapsed GBMs showed similar survival and proliferation index as compared to treatment-naïve tumors (Supplementary Fig. 1b, c, online resource). Based on the previous
experiments with GBM PDOXs generated in rats [111],
we were surprised to find that only a few PDOX models
in mice displayed extensive abnormalities in blood vessels.
Therefore, we compared identical patient GBMs implanted
in either mouse or rat brain. While invasive tumors were
similar in mice and in rats, vessel abnormalities were exacerbated in rats in the PDOXs showing only moderate defects
in the mouse brain (Fig. 1f, Supplementary Fig. 1d, online
resource), including pseudopalisading necrosis, dilated vessels, and endothelial cell proliferation. This indicates that the
capacity of human GBM to induce angiogenesis is higher
in rats as compared to mice, likely due to differences in size
and cross-species interactions. These interspecies differences
were also observed in xenografts derived from serum-free
GSC lines (Supplementary Fig. 1d, online resource).

Tumor development was independent
of non‑neoplastic cells present in organoids
Non-neoplastic cells of the TME constituted between 3 and
25% of all cells in tumor cores in different PDOX models
(Supplementary Fig. 1e, online resource) and these proportions remained stable over serial transplantations. To assess
whether the nontumor compartment present within organoids influenced tumor formation upon implantation in vivo,
we derived TME-free organoids from FACS-purified tumor
cells grown in eGFP-expressing mice and compared them
with TME-containing organoids (Supplementary Fig. 1f–g,
online resource). Both conditions allowed for reformation
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◂Fig. 2  Recapitulation of copy number aberrations in PDOXs. a

Pearson correlation between patient tumors, PDOXs, and cell lines
derived based on array-CGH genetic profiles (B, patient; X, PDOX;
C, cell line; adjacent numbers correspond to passage in vivo or
in vitro respectively). For statistics see Supplementary Fig. 2b, online
resource. b Array-CGH profiles of longitudinal samples (T192T233-T251) of patient LIH0192 showing retention of genetic aberrations upon recurrence after treatment (radio + chemotherapy).
The same profiles were recapitulated in PDOXs. c Example of an
array-CGH profile of a GBM patient and corresponding PDOX
model (T185 generation 1 and 4). No major changes were detected
upon serial xenotransplantation. Identical chromosomal breakpoints
are shown for EGFR amplicon and CDKN2A/B homozygous deletion. See more examples in Supplementary Fig. 2 and Supplementary Table 3, online resource. d Example of an IDH1mut glioma
patient and corresponding PDOX and cell line showing high genome
complexity. Patient was treated with radiotherapy before surgery. e
Array-CGH profiles of 3 pieces of the same tumor (T16) from patient
LIH0016 revealing intratumoral genetic heterogeneity (left panels). T16 PDOX and cell line were derived from additional MDM4/
EGFRΔ25-27-amplified clone. Right panels show the different amplicons in patient tumor fragments and PDOX

of 3D organoid structures from sorted cells. Comparison of
tumors derived from these two types of organoids showed
no significant difference in survival over serial transplantations (Supplementary Fig. 1g, online resource). The
resulting tumors appeared histologically similar, with the
expected level of invasion and the presence of an abnormal
vasculature. This shows that tumors quickly adapt to the new
microenvironment and recreate their niche in the brain by
recruiting host-derived TME at each passage.

Copy number alterations (CNAs) are well preserved
in glioma PDOXs
Glial tumors display considerable genetic heterogeneity,
with both inter- and intratumoral differences [91]. At the
DNA ploidy level, we have previously shown that GBMs
present as either mono- or polygenomic tumors where aneuploidy represents a late event in GBM evolution [92]. We
found that the PDOXs retain the patient tumor ploidy states
and that both pseudodiploid and aneuploid clones could be
propagated by serial implantation (Supplementary Table 1,
online resource). This is in contrast to long term cultures,
where GSC lines of pseudodiploid tumors undergo additional aneuploidization at early passages (Supplementary
Fig. 2a, online resource). By array-CGH, we show that at
scale CNAs of the parental tumors were maintained with
high fidelity in organoids and PDOXs both at low and high
generations (Fig. 2a, Supplementary Fig. 2b, c, Supplementary Table 3, online resource). PDOXs clustered next to or
in close proximity to their parental tumors. This was also
true for longitudinal gliomas, where similar genomic profiles were seen in recurrent tumors after treatment (Fig. 2b,
Supplementary Fig. 2d, online resource). Genomic aberrations were also assessed and confirmed by DNA Infinium
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Methylation EPIC arrays (Supplementary Table 3, online
resource). Most GBM patients harbored classical genetic
hallmarks, such as chromosome 7 gain, chromosome 10 loss
and CDKN2A/B deletion, which were all retained in PDOXs.
This is in contrast to subcutaneous PDXs, where classical
GBM CNAs where reported to be lost [7]. Moreover, focal
amplicons (e.g., EGFR, MDM2, MDM4, PDGFRA, MET,
CDK4/6) with the exact same breakpoints were maintained
in PDOXs over generations (Fig. 2c, Supplementary Fig. 2c,
online resource). IDH1mut gliomas, of which PDOXs could
be established, displayed a remarkable genomic complexity
(Fig. 2d, Supplementary Tables 1, 3, online resource).

Rare genetic discrepancies reflect intratumor
heterogeneity and tumor‑specific evolution
It has been suggested that tumors may undergo mousespecific tumor evolution in subcutaneous PDXs [7]. Here,
in our orthotopic xenografts, we only detected minor differences between PDOXs and patients, which could largely
be explained by clonal heterogeneity of the parental tumor,
particularly at the level of focal amplifications known to be
subclonal [45]. E.g., patient tumor T16 displayed intratumor
genetic heterogeneity, where differences in gene amplicons
for EGFR and MDM2 were detected in different tissue fragments dissected from the tumor core (Fig. 2e). Yet another
fragment carrying MDM4 and EGFR amplification with
Δ25−27 structural variant generated the initial 3D organoids and was further propagated in vivo over subsequent
passages. This was similar for PDOXs T341, P8 and T158
(Supplementary Fig. 2e, g, Supplementary Table 3, online
resource). These changes are most likely caused by tissue
sampling bias and selection of specific subclones upon
engraftment. Occasionally, we observed acquisition of
additional glioma-specific CNAs in later generations (e.g.,
+Chr16 and −Chr 6 in PDOX T101 G6, Supplementary
Fig. 2c, online resource; -1p21.1-p31.2 in PDOX P13, Supplementary Fig. 2i, online resource) in line with continuous tumor evolution over time. Of note, these rare events
occurred in individual tumors and always represented known
genetic aberrations in gliomas. We did not detect common
genetic modifications across the cohort which could be
linked to tumor growth in the mouse microenvironment,
as has been suggested for subcutaneous PDX [7]. Loss or
acquisition of new aberrations was much more common
in cultured GSC lines (Fig. 2e, Supplementary Fig. 2g–i,
Supplementary Table 3, online resource), including loss of
EGFR gene amplification and protein expression (Supplementary Fig. 2j, online resource), as noted previously [66].
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PDOXs recapitulate glioma driver mutations
and genetic heterogeneity
To further assess the mutational content and clonal architecture of patient tissues and matching organoids and PDOXs,
we applied targeted DNA sequencing to identify rare variants in disease associated genes using an extended gliomaspecific diagnostic panel (up to 234 genes) [85]. Overall
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the PDOX models showed excellent recapitulation of the
genetic variants identified in the patient tumors (Fig. 3a, b).
The rare differences were mainly due to variants detected
in patient tumors, but not in PDOXs tissues. These ‘lost’
variants were situated within chromosome regions deleted
in the tumor and often had an allele frequency < 50 % (Supplementary Table 4, online resource), suggesting that these
were germline variants with allelic loss in the tumor and

Acta Neuropathologica (2020) 140:919–949
◂Fig. 3  Recapitulation of DNA mutations and structural variants in

PDOXs. a Recapitulation of overall variants determined by targeted
sequencing. PDOXs were compared to respective patient tumors.
The number of total variants detected for each patient tumor and
PDOXs is displayed. b Summary of glioma specific somatic alterations including copy-number changes and mutations in patients and
their derivative preclinical models. Samples highlighted in gray represent longitudinal PDOXs. c Example of longitudinal GBM samples
(T192-T233-T251) of patient LIH0192 showing altered clonal distribution of EGFR structural variant vII to vIII upon relapse, which
is recapitulated in the respective PDOXs. Distinct EGFR genomic
regions deleted in respective variants are depicted. d Western blot
against EGFR (cocktail antibody recognizing wild-type (wt) and
structural variants) confirms protein expression of EGFRwt as well
as the respective structural variants EGFRvII (in T192) and vIII (in
T251) with decreased molecular weight. U87 cells overexpressing EGFRwt and EGFRvIII are shown for size reference. e Cellular
prevalence estimates from PyClone representing clonal populations
detected in longitudinal patient tumors and respective PDOXs. Examples shown for T192 and T251. Each cluster of mutations was computationally inferred to reflect a subclone. Number of genetic variants
contributing to each clone is depicted. f Cellular prevalence estimates
from PyClone representing clonal subpopulations detected in longitudinal patient LIH0192 and its respective PDOXs. Each line represents
a cluster of mutations computationally inferred to reflect a subclone.
Only genetic variants detected in all samples were considered for
analysis

likely originate from normal human tissue (TME) present
in the patients tumor, but not in the PDOX models. Only a
handful of genetic variants private to PDOXs were detected
and nearly all were located in noncoding regions (Fig. 3a,
Supplementary Table 4, online resource). In comparison,
PDOX-derived cell lines showed acquisition of further
new variants in cultures (Supplementary Fig. 3a, online
resource).
Targeted sequencing confirmed identified copy-number
alterations and further revealed specific mutations characteristic for gliomas (Fig. 3b, Supplementary Table 5, online
resource). Assessed IDH1mut gliomas (PDOX and parental tumor) carried mutations in ATRX and TP53 genes, in
line with the molecular diagnosis of astrocytomas obtained
by CpG methylation profiling [20] (Fig. 1b). Digital PCR
confirmed the presence of wild-type and R132H mutated
IDH1 alleles in PDOXs, although variations in ratio were
observed probably due to TME signal in patient tumors and
tumor aneuploidy (Supplementary Fig. 3b, online resource).
In line with previous reports [68, 88], in vitro GSC cultures drastically reduced IDH1 wild-type allele frequency in
T394NS, i.e., cells had lost wild-type IDH1 by passage 10,
whereas T407NS retained still 20% of the wild-type IDH1
allele at passage 13. This was combined with an acquisition of several new variants (Supplementary Fig. 3a, online
resource). IDHwt GBM PDOXs retained common glioma
mutations, including EGFR, MDM4, PTEN, PIK3CA, and
PTCH1 (Fig. 3b). One PDOX (P13) carried an IDH2 missense mutation (W244R) of unknown significance, which
has been described in the normal population (rs780131378)
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and is probably a rare private germline variant. It was not
associated with increased 2HG production (Supplementary
Table 5, online resource), and thus the tumor was considered
as IDHwt. The EGFR gene status was remarkably well preserved in the PDOXs. EGFR point mutations were detected
in the extracellular domain (A289T, G598V, F254I, R108K),
and co-occurred with EGFR amplification. EGFR structural
variants were present in the extracellular and/or intracellular
domains, such as Δ2-7 (EGFRvIII), Δ2-15, Δ6-7, Δ14-15
(EGFRvII), and Δ25-27 (Supplementary Table 5, online
resource). Notably, in agreement with a previous report [9],
PDOX P8 displaying EGFR A289T was one of the most
invasive and proliferative GBM.
In general, our matched longitudinal models retained similar coding variants upon recurrence (Fig. 3b). Interestingly,
LIH0192 patient tumor underwent heterogeneous complex
structural rearrangements leading to a shift from EGFRvII
to EGFRvIII upon relapse. These changes led to different
EGFR protein expression and were retained in the respective
PDOXs (Fig. 3c, d). LIH0347 patient-derived longitudinal
PDOXs retained EGFRΔ2-15, which also showed immunoreactivity to EGFRvIII antibodies (Supplementary Fig. 3c,
online resource).
We further used PyClone to follow the clonal dynamics upon engraftment of patient tissues and were able to
demonstrate that PDOXs retain genetic heterogeneity at
the subclonal level (Fig. 3e, Supplementary Fig. 3d, online
resource). Subclonal fractions were also retained in longitudinal models of patients LIH0192 and LIH0347, although
certain fluctuations in cellular prevalence were observed
(Fig. 3f, Supplementary Fig. 3e, online resource). Interestingly, we also observed evolutionary dynamics in EGFR
amplicons (Supplementary Fig. 3f, online resource), arising most probably from evolutionary trajectories of extrachromosomal double minutes [35]. In summary, glioma
PDOXs largely recapitulate genetic aberrations and genetic
heterogeneity of the parental tumors. Rare newly acquired
genetic features in PDOXs recapitulate glioma mutations
known in patients, suggesting that growth of human tumors
in the rodent brain can serve as a proxy for ongoing genetic
evolution in the brain microenvironment. This is in contrast
to in vitro passaging of glioma cells which regularly leads to
additional genetic aberrations which are not glioma specific.

Tumor intrinsic epigenetic profiles are preserved
in PDOXs
Cancer-specific DNA methylation patterns are important
drivers of gene expression and have been recognized as
a preferred prognostic biomarker used for brain tumor
subtyping [20, 22, 79]. Correlation analysis and principal component analysis (PCA) based on EPIC and 450K
Illumina DNA methylation arrays showed an overall good

13

936

Acta Neuropathologica (2020) 140:919–949

Fig. 4  DNA methylation profiling. a Pearson correlation of DNA
methylation profiles between glioma patient samples, PDOXs and
cell lines derived thereof based on 450 k and EPIC arrays (B, patient;
X, PDOX; C, cell line, overlapping regions between arrays only).
For statistics see Supplementary Fig. 4a, online resource. b Global
beta-value distributions are very similar between patient samples
and PDOXs. Cell lines displayed an increased DNA methylation at
open sea, shelf, and shore regions. c Beta-value distributions are very
similar upon tumor recurrence and are recapitulated in corresponding PDOXs. Examples are shown for longitudinal samples of patients

LIH0192, LIH0347, and LIH0394, the latter being IDH1mut. d Mean
beta-value distribution in patients and PDOXs show increased methylation in a subset of CpG islands and decreased methylation of tiling regions in PDOXs. CpG sites with FDR < 0.05 are displayed in
red, remaining probes are shown in blue. e Examples of hypo- and
hypermethylated CpG islands in PDOXs. GFAP is widely expressed
in GBM, whereas IRF6 is involved in innate immune response. Differentially methylated sites are changing from hemi-methylated in
patient tumors to either unmethylated (GFAP) or methylated (IRF6)
status in PDOXs

correlation between patient tumors and PDOXs (Fig. 4a,
Supplementary Fig. 4a, online resource), where samples
clustered based on IDH status. Although sample type also

contributed to the source of variation in the cohort, the
IDH status was the main source of variation (Supplementary Fig. 4b, online resource). IDH1mut gliomas displayed
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divergent DNA methylation of specific CpG islands compared to IDHwt gliomas (Supplementary Fig. 4c, online
resource). Yet, G-CIMP-low subtype dominated our IDH1mut patient tumors and PDOXs (Supplementary Table 6,
online resource), presumably in line with their increased
aggressiveness [33]. The beta-value distributions were
very similar between PDOXs and parental tumors, whereas
GSC lines displayed increased DNA methylation at open
sea, shelf, and shore genomic regions (Fig. 4b). This was
supported by PCA analysis showing a lower similarity
of GSC lines to patient tumors in comparison to PDOXs
(Supplementary Fig. 4a, online resource). This was true
for IDH1wt and mutated cell lines (Supplementary Fig. 4a,
d, online resource). Importantly, the MGMT promoter
DNA methylation status was preserved between PDOX
and parental tumor in all but two PDOXs (Supplementary
Table 6, online resource). Global DNA methylation profiles based on beta-value distributions were also well preserved in longitudinal glioma samples between each other
and with their respective PDOXs. Overall, most tumors
retained the same DNA methylation profile upon recurrence (Fig. 4c), including MGMT promoter methylation
status (Supplementary Table 6, online resource), although
differences at individual CpG sites are possible.
Statistical analysis of paired methylation profiles revealed
only minor changes between patient tumors and respective
PDOXs (Limma, FDR < 0.01). Only 35 individual CpG sites
showed differences in mean methylation beta values above
0.4, corresponding to an essential switch in DNA methylation status, but none were gene annotated CpGs. A partial
change of DNA methylation levels (beta value difference
0.2–0.4) was observed at CpG sites of 226 CpG islands,
89 promoters, 74 gene bodies and 943 tiling regions. Most
sites that were demethylated in PDOX corresponded to tiling
regions that changed from hemi- to unmethylated (894/943,
Fig. 4d), pointing towards global hypomethylation characteristic for high-grade glioma [22]. This was also true for
certain gene promoters specific to GBM cells (e.g., GFAP,
Fig. 4e). An increase towards fully methylated CpG sites
was observed typically at CpG islands (196/226, Fig. 4d),
including promoters of genes expressed classically by the
TME (e.g., IRF6 for immune cells, Fig. 4e), reflecting the
impact of non-neoplastic cells on methylation profiling [56].
Accordingly, the molecular classification based on previously defined DNA methylation classes [20, 22, 33] was
well retained in PDOXs (Fig. 4a, Supplementary Table 6,
online resource). Class switches between patient and PDOX
occurred from mesenchymal-like to classic-like tumors
(LGm5 to LGm4, mesenchymal to RTK II class, Supplementary Table 6, online resource), in line with the influence
of the TME on DNA methylation profiles as has also been
shown for gene expression signatures [112]. GSC cell lines
displayed more divergent DNA methylation profiles with
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increased DNA methylation levels (Fig. 4a, b) and were not
clearly classified (Supplementary Table 6, online resource).
Although we did not detect a link between treatment history
of patient tumors and molecular subtypes, more data will
be required in the future to perform meaningful statistical
analyses.

Gene expression analysis reveals close resemblance
between patient tumors and PDOXs
To determine to what extent gene expression profiles of
parental tumors are retained in glioma PDOXs, we performed genome-wide transcript analysis using humanspecific microarrays (Fig. 5a). In parallel, we analyzed cell
cultures and corresponding intracranial xenografts from
GSC (NCH421k, NCH644) and adherent cell lines (U87,
U251). Unsupervised hierarchical cluster and PCA analyses revealed close resemblance of PDOXs to corresponding
patient tumors, although higher similarity of samples of the
same type was observed (Fig. 5a, Supplementary Fig. 5a,
online resource). Cell lines and their xenografts were more
dissimilar and clustered according to their origin, in line
with a higher cellular selection and adaptation in long term
in vitro cultures. Transcriptomic profiles of PDOXs also displayed strongest similarity to GBMs from the TCGA cohort
[19] (Supplementary Fig. 5b, online resource). Analysis of
transcriptomic subtypes revealed differences when using
the original molecular signatures proposed by Verhaak
et al. [107]. However, with the recent tumor-intrinsic classification aimed at reducing the influence of TME [112],
the subtyping remained constant (Supplementary Table 7,
online resource), suggesting that transcriptomic differences
between patient tumors and PDOXs arise from TME-associated gene expression. Cell lines retained transcriptomic
subtypes were retained upon in vivo growth. Analysis of
differentially expressed genes between PDOXs and parental
tumors (2-way ANOVA, FDR<0.01, absFC≥2) revealed an
increase in tumor intrinsic signals such as cell cycle and
DNA repair (Fig. 5b), which was most prominent in highly
proliferative PDOXs (P3, P8, P13, Fig. 5c). Genes downregulated in PDOXs were associated with TME processes,
i.e., immune response, angiogenesis and macrophage activation (Fig. 5b, c). Specific markers of human TME components such as endothelial cells (VWF, KDR), microglia/macrophages (ITGAX, AIF1, CD68), pericytes/vascular smooth
muscle cells (PDGFRB, ACTA2) and hematopoietic cells
(CTLA4, CD4, PTPRC) were depleted in PDOXs (Fig. 5c).
This included also ABCB1 and ABCG2, which we have previously shown to be restricted to brain endothelial cells in
human GBM [47]. The general depletion of human TME
transcriptome upon xenografting was confirmed by independent component analysis (Fig. 5d) and flow cytometry
(Fig. 5e). Interpatient differences were retained in PDOXs,
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◂Fig. 5  Transcriptomic profiles and intratumoral heterogeneity. a Pear-

son’s correlation indicating similarity of genome-wide gene expression profiles between normal human brain, glioma patient samples,
PDOXs, GSC lines (NCH421k, NCH644) and classical glioma
lines (U87, U251) grown in vitro or as xenograft (‘X’). Human specific arrays were applied for transcriptome analysis. b Summary
of main GO terms characterizing genes differentially present in
PDOXs (FRD ≤ 0.01, ab(FC) ≥ 2, Limma). c Heatmap representing gene expression levels for a selection of classical TME and cell
cycle markers in normal brain (NB), patients and respective PDOXs.
d Independent component analysis showing depleted transcriptomic
signals associated with immune response and neuronal ensheathment
in PDOXs and cell lines. Cell cycle independent component (IC) was
the highest in PDOXs and cell lines, cell migration-associated IC
was the highest in patients and PDOXs. e Flow cytometric analysis
to detect human cell subpopulations in patient samples and respective
PDOXs. Examples are shown for PDOX T331 expressing EGFR in
tumor cells. f Single cell signatures showing the presence of human
tumor cells in distinct phases of cell cycle and hypoxic gradient in
PDOXs. g Assessment of GBM cellular states [77] and TCGA GBM
subtypes [112] at single cell level in PDOX tumor cells

e.g., EGFR expression was maintained at similar levels as
in patients (Fig. 5c). We did not detect an upregulation of
specific molecular pathways linked to stemness (i.e., cancer stem-like profiles), confirming the lack of a particular
selection for tumor subpopulations. Indeed, the heterogeneous expression of stem cell markers in GBM, as previously reported [36], was retained in the respective PDOXs
(Fig. 5e) and remained largely stable over serial transplantations (Supplementary Fig. 5c, online resource). Transcriptomic analysis at the single cell level revealed similar
proportions of cycling cells and the presence of a hypoxic
gradient in PDOX (Fig. 5f) as shown for GBM patients [81].
PDOXs also recapitulated intratumoral heterogeneity and
phenotypic cellular states previously described in GBM
patients [77, 112] (Fig. 5g). Mouse-derived TME, which
replaced human TME, showed similar cellular subpopulations as detected in patient tumors including microglia/
macrophages, oligodendrocyte progenitor cells (OPCs) and
astrocytes comparable to human GBM TME [31] (Supplementary Fig. 5d, online resource). In conclusion, our data
show that glioma PDOXs recapitulate well tumor-intrinsic
transcriptomic profiles. Differences in gene expression signatures at the bulk level can be explained by the replacement of the human TME by mouse cells undergoing GBMspecific adaptation.

Preclinical drug testing in PDOX‑derived
standardized 3D glioma organoids provides
clinically relevant outcomes
The PDOX cohort described above constitutes a living
biobank maintained by serial transplantation of organoids
obtained through mechanical cutting of tumor tissue. This
allows to expand the patient tumor in its natural brain
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microenvironment, generating sufficient material for large
scale preclinical drug testing. To this aim, we standardized the derivation of uniform GBM organoids amenable
for reproducible drug screening. Organoids were generated
from 1000 MACS-purified single tumor cells obtained from
PDOXs, which were able to self-organize into 3D organoids
within 72h in nonadherent conditions (Fig. 6a). This allowed
for sensitive evaluation of cell viability and toxicity in a 384well plate format (Supplementary Fig. 6a, online resource),
similar to protocols described for other types of cancer
organoids [44]. To assess whether PDOX-derived organoids
recapitulate known mechanisms of drug sensitivity and
achieve clinically relevant responses, we subjected a cohort
of 18 GBM PDOXs to temozolomide (TMZ), the standard
DNA-alkylating agent in clinical practice. Cell responses
were calculated as the Area Under the Curve (AUC). In
accordance with clinical data, GBM organoids showed only
a partial response to TMZ (AUC 200-600, Fig. 6a, b, Supplementary Fig. 6b, online resource). Importantly, tumors
with a methylated MGMT promoter appeared less resistant
in comparison to MGMT promoter-unmethylated GBMs
(Fig. 6c, Supplementary Fig. 6b, online resource). No differential response was observed between treatment-naïve
organoids and organoids derived from patients previously
exposed to chemoradiotherapy (Supplementary Fig. 6c,
online resource).

Dianhydrogalactitol (VAL‑083) exhibits strong
efficacy against GBM independent of (epi)genetic
background and treatment history
We further tested dianhydrogalactitol (VAL-083), a
bifunctional compound able to alkylate N7-guanine and
form interstrand crosslinks and DNA double strand breaks
[117]. VAL-083 is known to penetrate the blood–brain
barrier and to accumulate in the cerebrospinal fluid and
brain parenchyma [39]; it is currently tested in clinical trials for recurrent GBM (NCT02717962) as well as for treatment-naïve MGMT promoter unmethylated GBM patients
(NCT03050736). In our cohort, VAL-083 was significantly
more effective than TMZ (Fig. 6a, b) and the response
was not dependent on MGMT promoter methylation status (Fig. 6c). The response was similar in treatment-naïve
and relapsed organoids (Supplementary Fig. 6c, online
resource), suggesting that VAL-083 is able to overcome
TMZ resistance. In view of the strong efficacy of VAL-083
in the ex vivo assay we evaluated its ability to decrease
tumor growth in vivo. Due to the structural similarity with
glucose, we hypothesized that uptake of VAL-083 could
be further enhanced under hypoxia; we therefore also
applied a combination treatment with the antiangiogenic
agent Bevacizumab previously shown to induce hypoxia
in GBM [1, 53]. As expected, Bevacizumab treatment
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did not halt tumor progression despite decreased contrast
enhancement on MRI (Fig. 6d) and blood vessel normalization (Supplementary Fig. 6d, online resource). VAL-083
monotherapy led to a dramatic reduction in tumor growth
(Fig. 6e), an effect which was only mildly accentuated by
combined treatment. Histological assessment of tumorcontaining brains confirmed the strong reduction in tumor
volume upon VAL-083 treatment (Supplementary Fig. 6e,
online resource). This was paralleled by an increase in
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DNA damage in tumor cells, determined by H2AX phosphorylation (H2AX-P) (Supplementary Fig. 6f, online
resource). Limited H2AX-P was also seen in normal brain
cells close to the meninges and the subventricular zone,
but to a much lower extent than in tumor cells. In summary, we show that VAL-083 has a consistently favorable
drug profile against GBM; thus, representing a promising
candidate for GBM treatment either alone or in combination with antiangiogenic compounds.
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◂Fig. 6  Drug response assessment in glioma organoids and PDOXs.

a Drug response was evaluated in PDOX-derived organoids with
standardized size (green, viable; red, dead cells). Representative
images are shown for TMZ and VAL-083 treatment of T434-derived
organoids. Scale bar = 50 µm. b Quantification of AUC upon exposure to TMZ and VAL-083. Mean AUC ± SEM is shown for each
model. Experiment was performed once with three technical replicates per PDOX per drug concentration. VAL-083 is generally
more effective in PDOX-derived organoids in comparison to TMZ
(***pvalue < 0.001, unpaired t test). c Mean AUC upon exposure to
TMZ and VAL-083 in MGMT promoter methylated and unmethylated tumors. Tumors with methylated MGMT promoter show
enhanced response to TMZ, while response to VAL-083 is independent of the MGMT promoter status (**pvalue < 0.01, unpaired t
test). d PDOX T16 treated in vivo with VAL-083, Bevacizumab or
a combination. Tumor progression was assessed by T1-weighted
and T2-weighted MRI images (n = 6–7 mice per group) prior treatment (day 35) and post treatment (day 49 and 56 equivalent of 14
and 21 days since beginning of treatment respectively). e Assessment of tumor progression over time reveals significant reduction of
tumor growth upon VAL-083 treatment. Tumor growth rate between
treatment groups was calculated during the entire study (day 35 vs.
day 56, n = 6–7, ***pvalue < 0.001, **pvalue < 0.01, ANOVA with
Tukey’s Multiple Comparison Test). f Quantification of AUC upon
exposure to EGFR inhibitor Erlotinib showing higher sensitivity in
EGFR mutated tumors (vs EGFR wild type) and in EGFR amplified
tumors (vs EGFR nonamplified). This is also recapitulated at the level
of EGFR protein expression. No significant effect is seen for tumors
with or without EGFR variants. (*pvalue < 0.05, unpaired t test); wt,
wild type; mut, mutated; Amp, amplified; SV, structural variant;
EC, extracellular domains; IC, intracellular domains; exp, expression. g Quantification of AUC upon exposure to CDK4/6 inhibitors
Palbociclib and Abemaciclib shows higher sensitivity of CDK4 and
CDK6 amplified tumors (vs nonamplified tumors). (*pvalue < 0.05,
**pvalue < 0.01, unpaired t test). For f–g experiments were performed
twice with 3 technical replicates each. See Supplementary Table 8
for mean AUC ± SEM. h High-throughput screening with 42 FDAapproved drug library in PDOX T434. Drug response data are displayed as normalized AUC +/−SEM, (n = 2), ‘−1’ value is indicated
as a threshold for strongest hits

PDOX‑derived organoids are amenable
to high‑throughput drug screening for precision
medicine
To evaluate the potential for personalized treatment regimens
of our models, we functionally assessed the response against
a set of EGFR/ErbB small-molecule tyrosine kinase inhibitors (Erlotinib, Gefitinib, AZD3759, AG490, and Daphtenin)
and CDK4/6 inhibitors (Abemaciclib, Palbociclib) with varying specificity in 16 PDOX-derived organoids with variable
genetic makeup of these pathways. The inability to preserve
gene amplification and EGFR structural variants in most cell
culture models including GSCs [66], did so far not allow
for accurate personalized preclinical studies. Our testing
group included GBM with different status of CDK4, CDK6,
and EGFR amplification, EGFR genetic variants and point
mutations (Fig. 3b, Supplementary Table 5, online resource).
The responses against EGFR inhibitors were highly variable
across patient organoids (Fig. 6f, Supplementary Fig. 6g,
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online resource). In contrast to kinase domain mutations
found in lung cancer, glioma-specific extracellular domain
mutants are known to respond poorly to EGFR inhibitors
[64]. Still, we found that GBMs carrying EGFR mutations,
except for EGFR F254I (PDOX T434), were more sensitive
to Erlotinib and AZD3759, but not to the other EGFR inhibitors, Gefitinib, AG490 and Daphtenin (Fig. 6f and Supplementary Fig. 6g, online resource). This is in accordance with
the fact that EGFR R108K, G598V, and A289T are missense
mutations leading to a gain-of-function, shown previously to
sensitize tumors to Erlotinib [63]. The role of EGFR F254I
is currently unclear. EGFR amplification and corresponding
high protein expression also had an impact on the sensitivity
to Erlotinib and AZD3759, where nonamplified tumors with
low protein expression were most resistant. EGFR structural
variants did not sensitize tumors in our cohort to any of the
five compounds. Similarly, tumors carrying CDK4 (PDOX
T434) and CDK6 (PDOX T341) amplification were most
sensitive to CDK4/6 inhibitors Palbociclib and Abemaciclib
(Fig. 6g).
Finally, we performed a proof-of-concept study on
PDOX-derived organoids for high-throughput drug screening using the cell printing technology based on the ASFA
Spotter ST [37]. PDOX T434 derived GBM cells were dispensed onto pillars (1000 cells per pillar), embedded into
alginate drops and allowed to reform 3D organoids (Fig. 6h).
A library of 42 FDA-approved drugs was then applied for 7
days and response was assessed via a High Content imaging system (CV 8000) recognizing viable cells. To select
the strongest hits, we applied normalized AUCs (Z score,
− 1 threshold) [64]. The screen showed similar responses as
the 384-well plate protocol (Supplementary Fig. 6h, online
resource), and confirmed sensitivity of T434 tumor cells to
Abemaciclib and resistance to Erlotinib and Gefitinib. Interestingly, it revealed sensitivity to several other inhibitors,
including Afatinib,—a second-generation EGFR inhibitor. In
summary, we show that PDOX-derived GBM organoids display clinically relevant drug responses and can be applied for
personalized drug screening in a high-throughput manner.

Discussion
Although major discoveries can be performed directly on
patient tumors, biological material is restricted, generally limiting such studies to descriptive analyses and lowthroughput preclinical assays. Here we present a living
tumor biobank that encompasses the clinical diversity of
high-grade diffuse gliomas. Over 160 organoids and 40
PDOX models were established from treatment-naïve glioma patients and patients that underwent standard-of-care,
of which 15 represent paired longitudinal models. Glioma
organoids grown in PDOX, combines the generation of a
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powerful in vivo model for precision oncology with the
expansion of patient tumor material in an appropriate TME
setting not possible in vitro. Our PDOX cohort contains
tumors of varying genetic and molecular background, and
represents a unique tool for drug screening, functional studies and in vivo drug efficacy studies. We show that glioma
PDOXs recapitulate (1) glioma tissue architecture, including
features of angiogenesis and invasion, (2) genetic variants
and CNAs, including rare gene amplifications (3) epigenetic
and transcriptomic tumor intrinsic signatures, (4) intratumoral genetic, transcriptomic, and stem-cell-associated
heterogeneity, (5) clinically relevant drug responses. Our
models and associated molecular data are openly shared and
available at the PDXFinder portal (https://www.pdxfinder.
org/) and via the EurOPDX consortium (https://www.europ
dx.eu/). They represent a robust tool for reliable expansion
of patient tumor material while maintaining close identity
with the parental tumors, allowing for high-throughput drug
testing and precision medicine.
Most available glioma PDX models are established and
maintained through subcutaneous implantation of tumor
fragments [21, 106], where the long term impact of a nonbrain TME is unclear. Orthotopic GBM xenografts usually
rely on single cell dissociation followed by in vitro cultures
as GSCs (BTICs) prior to xenotransplantation [21, 35, 49,
52, 108], where cultures are often maintained for unspecified time and passage number. To minimize the loss of tissue
architecture and clonal heterogeneity, we use organoids from
mechanically minced glioma tissue, only briefly maintained
in culture without any in vitro passaging. In order to maintain the heterogeneous nature of the primary tumor within
self-organizing organoids, we did not try to achieve indefinite growth of organoids in vitro [49, 51], instead we orthotopic xenografting for tissue expansion and maintenance.
We find that most GBMs and lower grade gliomas give rise
to short-term organoids. Successful PDOX establishment
enriches for high-grade tumors, including IDHwt GBMs and
IDH1mut gliomas grades III and IV. This is in concordance with the general selection of aggressive tumors upon
PDX generation in different tumor types, including pediatric
brain tumors [13]. So far, only a handful of IDH1mut glioma models have been described, which all suffer from poor
reproducibility, a long development time and/or changes in
IDH1 status [55, 69, 75, 99, 106, 109]. Successful IDH1mut models in our cohort were defined molecularly as highgrade astrocytomas with abundant chromosomal aberrations,
CDKN2A/B loss, ATRX, and TP53 mutations and G-CIMPlow signature. These molecular features correspond to the
most aggressive IDH1mut gliomas [5, 33, 109]. Importantly,
our models retain R132H IDH1 heterozygosity and efficient
production of 2HG [43]. In vitro cultures derived from these
tumors either died or led to depletion of the wild-type IDH1
allele, in line with previous reports [68, 104], suggesting that
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IDH1mut gliomas require components of the brain microenvironment to maintain their growth. Importantly, our fully
annotated cohort displays a wide variety of genetic features
not recapitulated in other models (e.g., EGFR and PDGFRA
amplification), thus reflecting the wide interpatient heterogeneity of high-grade gliomas. Our PDOX biobank also
contains 15 unique paired models derived from the same
patients at initial diagnosis and upon disease relapse.
The recapitulation of histopathological features of gliomas has been challenging with classical serum-grown cell
lines, as they largely lose the characteristic invasive potential
of diffuse gliomas upon xenotransplantation [28, 71]. Infiltrative growth is maintained in all our PDOXs, although the
extent of typical glioma features, including invasion, angiogenesis, and proliferation rate can greatly vary across models, likely reflecting interpatient heterogeneity. We find that
prominent angiogenic features along with pseudopalisading
necrosis are rare in mice compared to rats, which may arise
from differences in brain size and/or in molecular interaction
between species. This suggests that for studies addressing
aspects of angiogenesis, hypoxia, and blood–brain barrier,
rat PDOX models may be more appropriate. Others have
also reported gradients of invasive and angiogenic features
across GBM xenografts, with limited endothelial proliferation and necrosis in mouse brains [106, 109], while large
subcutaneous tumors display extensive angiogenesis [106].
We have previously shown that GBM organoids and corresponding PDOXs faithfully retain tumor cell ploidy [92].
Here we demonstrate that glioma organoids and PDOXs
accurately maintain distinct genetic backgrounds of parental
tumors, including gene amplifications of EGFR, PDGFRA,
MET, MDM2/4, and CDK4/6, which are difficult to derive
and preserve in vitro [66, 88]. PDOXs also recapitulate complex EGFR variants and mutations present concomitantly
with EGFR amplification. At scale, we found that individual
genomic profiles are highly conserved in PDOXs. We did not
detect major divergences in CNAs as reported for subcutaneous GBM PDXs [7]. The difference in results may be related
to the subcutaneous transplantation, which may lead to a
different tumor evolution than in the brain. Alternatively, it
may be due to differences in data analysis, since array-CGH
based CNA determination, employed by us, is known to be
more accurate than CNAs inferred from gene expression
profiles [115]. We further observed extensive preservation of
genetic intratumoral heterogeneity, although some fluctuations in subclonal architecture were detected. Interestingly,
we report a case of EGFR variant selection, observed both
upon tumor relapse in patients as well as upon xenografting.
This may be linked to high levels of EGFR amplification and
the presence of extrachromosomal double minute structures,
which are known to show evolutionary dynamics [35].
In rare cases PDOX models showed engraftment or
expansion of specific genetic clones, with distinct gene
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amplifications or mutations, differing from the originating
tumor. Genomic events that were private to the PDOX correspond to classical glioma aberrations, known to be heterogeneous late events in GBM [54, 96], supporting the notion
that the PDOX-dominating clones were a result of original
intratumor heterogeneity revealed by sampling and natural
glioma evolution over time. In contrast to a previous analysis
of subcutaneous PDX [7], we did not detect any recurrent
genetic changes across the cohort suggesting that the interaction of human tumor cells with mouse TME does not influence genetic features of the tumor per se. Minor changes in
clonal trajectories have also been observed in certain PDX
from GBMs [106], brain metastases [101] and other cancers
[40, 46]. In this respect, PDOX models can be considered as
a proxy for dynamic clonal evolution, which is difficult to
measure in patients. We also did not observe major changes
in paired longitudinal glioma samples neither in the parental
patient tumor nor in the corresponding PDOX, in accordance with limited treatment-induced clonal evolution in diffuse gliomas [5]. We report a case of clonal evolution from
EGFRvII to EGFRvIII, which was recapitulated in the corresponding PDOXs. Although EGFRvIII may be lost upon
recurrence, cases with acquisition of this variant were also
reported [38, 110]. Interestingly, longitudinal models also
retained state-specific intratumoral heterogeneity and genetic
subclones, highlighting the notion that these unique matched
PDOXs provide an ideal platform to study specific molecular
events in initial and recurrent disease side by side. We further show that propagation of GBM cells grown as GSCs in
vitro leads to a faster genetic drift, including ploidy changes,
and acquisition of new CNAs and genetic variants.
At scale tumor-intrinsic epigenetic and transcriptomic
profiles of individual tumors were well recapitulated in
PDOX. Our PDOX cohort represents diverse molecular subtypes and retains intratumoral heterogeneity and plasticity, in
particular, we show that GBM PDOX display cellular state
transitions recently described in patient samples [77]. No
major molecular changes or selection of cellular subpopulations were detected, except for those related to the replacement of human TME by mouse counterparts. These changes
are expected in bulk tissue analyses where methylation and
transcriptome profiles are biased by TME-derived signals
[56, 112]. In line with the previous reports [6, 88] in vitro
cell lines showed increased global DNA methylation levels
and more profound changes in transcriptomic profiles.
Limitations of PDOX models include possible interspecies differences at the molecular level and the lack of a
complete immune system in immunocompromised animals.
While the adaptive immune system is largely absent in these
mice, they retain a largely functional innate immune system, including microglia, the brain resident immune effector cells, and peripheral myeloid cells. GBM are largely
lymphocyte depleted tumors[102], while microglia and
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macrophages constitute the major immune component [82].
Here we show that classical glioma TME components such
as microglia/macrophages, astrocytes, and OPCs are present
in xenografted tumors, indicating that tumor cell interactions
with the TME remain active in PDOX. Of note, we observe
a similar transcriptomic shift in tumor-associated microglia/macrophages as described in GBM patients [31, 113].
It remains to be determined to what extent these models will
be amenable to immunotherapeutic studies targeting tumorassociated microglia/macrophages. Although challenging,
adaptation of glioma PDOXs to a humanized background
might be possible and/or studies in an immunocompetent
context could be performed with PDOX-derived organoids
co-cultured with autologous immune cells.
Other drawbacks of patient-derived (orthotopic) xenografts, include high costs, complex logistics and an inherent
low-throughput nature. Large-scale in vivo screens are possible; however, they are laborious and require specific statistical settings [46]. Expansion of human gliomas in PDOX and
initial drug screens performed on PDOX-derived organoids
appears as a good compromise between retention of glioma
hallmarks and a cost-effective drug testing pipeline. In contrast to patient-derived short-term cultures and organoids
[51, 64], it allows for tumor expansion and in vivo validation. We have developed our protocols to reconstitute 3D
organoids of equal size, which allow for reproducible drug
testing. Downscaling of cell number per organoid facilitated
drug delivery, viability detection, and upscaling to highthroughput screens. These protocols can also be adapted to
reintroduce TME components [12] and immune cells. We
show that PDOX-derived organoids show clinically relevant
responses: (1) organoids with MGMT promoter methylation
showed higher sensitivity to TMZ, (2) CDK4/6 amplified
organoids responded better to CDK4/6 inhibitors, (3) organoids carrying EGFR R108K, G598V, and A289T gain-offunction mutations were most sensitive to Erlotinib and
AZD3759, whereas EGFR low tumors were most resistant.
Although EGFRvIII [73] and deletions in the C-terminal
domain (Δ25-27/28) were shown to sensitize GBM cells to
Erlotinib [25], none of the EGFR structural variants present in our testing group systematically sensitized tumors
to any of the EGFR inhibitors. Of note, the tested organoids
displayed PTEN loss, a known resistance factor leading to
dissociation of EGFR inhibition from downstream PI3K
pathway inhibition [73]. Remarkably, VAL-083 showed a
significantly better response than TMZ against GBMs of different genetic backgrounds and irrespective of MGMT status.
VAL-083 was able to overcome TMZ resistance in recurrent
GBM and its efficacy was confirmed in vivo, with no toxicity
observed, lending optimism to ongoing clinical trials.
Overall, our glioma PDOX cohort provides a powerful
platform for understanding tumor biology and preclinical
treatment interventions at the individual patient level. So
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far, the co-clinical use of glioma PDOXs as patient avatars
for treatment prediction remains challenging as in most
cases the time to establish PDOXs in sufficient quantity
required for preclinical drug testing (generation 2-3) takes
longer than the survival of most high-grade glioma patients.
Instead, PDOXs can play a key role as a preclinical platform
in ‘mouse clinical trials’ [114] for personalized medicine
regimens. Organoid cultures are further an excellent tool
for high-throughput drug intervention studies at lower cost
and can be used directly either established from the patient
tumor tissue or from PDOXs. Longitudinal models further
constitute a robust tool for the analysis of tumor evolution
and resistance mechanisms following targeted or untargeted
treatments. By sharing the models and molecular data, we
aim to facilitate large collaborative future preclinical trials.
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